 
 
 
 
 
 
 
G
EO
S
CAN
 
AND
 
R
EMOTE
 
G
EO
 
S
MOKING
 
S
TUDY
:
 
N
EURAL
 
AND
 
B
EHAVIORAL
 
C
ORRELATES
 
OF
 
S
MOKERS
'
 
E
XPOSURE
 
TO
 
R
ETAIL
 
E
NVIRONMENTS
 
 
 
 
 
Principal
 
Investigator
 
 
[INVESTIGATOR_510049],
 
Ph.D.
 
Annenberg
 
School
 
for
 
Communication
 
University
 
of
 
Pennsylvania
 
  [ADDRESS_659403],
 
Philadelphia,
 
PA
 
[ZIP_CODE]
 
 
  [PHONE_10577]
 
 
[EMAIL_9685]
 
 
 
 
 
Funding
 
Sponsor
 
National
 
Cancer
 
Institute
 
(NCI)
 
  National
 
Institutes
 
of
 
Health
 
(NIH)
 
[ADDRESS_659404],
 
Rockville,
 
MD
 
[ZIP_CODE]
 
[PHONE_421]
 
 
 
Protocol
 
Number
 
 
IRB
 
Number
 
ClinicalTrials.gov
 
Identifier:
 
[STUDY_ID_REMOVED]
 
 
 
IRB
 
850796
 
ACC
 
Identifier:
 
U
PCC#
 
[ZIP_CODE]
 
 
NIH
 
Grant
 
Number
 
 
1R01CA229305-01A1
 
 
 
 
 
Version:
 
 
 
 
Version
 
06/02/2025
 
 
 
V2025-06
 

 
Table
 
of
 
Contents
 
â—
 
Background
 
and
 
Study
 
Rationale
 
[ADDRESS_659405]
 
Recruitment
 
13
 
5
 
Study
 
Procedures
 
14
 
5.1
 
Screening
 
14
 
5.1.1
 
Screen
 
A
 
14
 
5.1.2
 
Initial
 
Call
 
14
 
5.1.3
 
Screen
 
B
 
15
 
5.1.4
 
Mailing
 
Materials
 
15
 
5.2
 
Study
 
Observational
 
Phase
 
15
 
5.2.1
 
Online
 
Session
 
1
 
(S1)
 
[ADDRESS_659406]
 
20
 
6.3.3
 
Interim
 
Analysis
 
22
 
7
 
Safety
 
and
 
Adverse
 
Events
 
23
 
7.1
 
Definitions
 
23
 
7.1.1
 
Adverse
 
Event
 
23
 
7.1.2
 
Serious
 
Adverse
 
Event
 
23
 
7.2
 
Recording
 
of
 
Adverse
 
Events
 
23
 
7.3
 
Relationship
 
of
 
AE
 
to
 
Study
 
24
 
7.4
 
Reporting
 
of
 
Adverse
 
Events
 
and
 
Unanticipated
 
Problems
 
24
 
7.4.1
 
Follow-up
 
Report
 
24
 
7.4.2
 
Investigator
 
reporting:
 
notifying
 
the
 
study
 
sponsor
 
[ADDRESS_659407]
 
Keepi[INVESTIGATOR_007]
 
26
 
8.1
 
Confidentiality
 
26
 
8.2
 
Data
 
Collection
 
and
 
Management
 
27
 
9
 
Study
 
Monitoring,
 
Auditing,
 
and
 
Inspecting
 
29
 
9.1
 
Study
 
Monitoring
 
Plan
 
29
 
9.2
 
Auditing
 
and
 
Inspecting
 
30
 
10
 
Ethical
 
Considerations
 
30
 
10.1
 
Risks
 
30
 
10.2
 
Benefits
 
31
 
10.3
 
Risk
 
Benefit
 
Assessment
 
31
 
10.4
 
Informed
 
Consent
 
Process
 
/
 
HIPAA
 
Authorization
 
[ADDRESS_659408]
 
S
TIPENDS
 
OR
 
P
AYMENTS
 
32
 
12
 
Publication
 
Plan
 
33
 
13
 
References
 
34
 
 
V2025-06
 

 
Study
 
Summary
 
 
Title
 
Remote
 
Geo
 
Smoking
 
Study:
 
Behavioral
 
and
 
Geospatial
 
Correlates
 
of
 
Smokers'
 
Exposure
 
to
 
Retail
 
Environments
 
Short
 
Title
 
Remote
 
Geo
 
IRB
 
Number
 
850796
 
Methodology
 
This
 
study
 
will
 
utilize
 
a
 
randomized
 
trial
 
to
 
examine
 
the
 
effects
 
of
 
point-of-sale
 
tobacco
 
marketing
 
on
 
smoking
 
behaviors
 
and
 
brain
 
activity.
 
After
 
a
 
two
 
week
 
observational
 
period,
 
participants
 
will
 
be
 
randomized
 
to
 
one
 
of
 
three
 
behavioral
 
intervention
 
conditions
 
for
 
the
 
duration
 
of
 
a
 
four
 
week
 
intervention
 
period.
 
 
Study
 
Duration
 
Five
 
years
 
 
Study
 
Center(s)
 
Single-center
 
Objectives
 
â—
 
The
 
primary
 
objectives
 
of
 
this
 
study
 
are
 
to
 
understand
 
the
 
effects
 
of
 
point-of-sale
 
tobacco
 
marketing
 
(POST-M)
 
on
 
smoking
 
behavior
 
and
 
cravings
 
in
 
smokers.
 
We
 
will
 
examine
 
whether
 
experimental
 
group
 
assignment
 
affects
 
cigarette
 
cravings
 
and
 
cigarette
 
consumption
 
during
 
the
 
intervention
 
period
 
relative
 
to
 
the
 
baseline
 
period.
 
 
â—
 
For
 
a
 
subset
 
of
 
participants,
 
we
 
will
 
examine
 
brain
 
responses
 
during
 
the
 
smoking
 
cue
 
reactivity
 
task.
 
Number
 
of
 
Subjects
 
343
 
[Actual]
 
Main
 
Inclusion
 
and
 
Exclusion
 
Criteria
 
Key
 
Inclusion
 
Criteria
 
for
 
remote
 
participation:
 
â—
 
Be
 
between
 
the
 
ages
 
of
 
21-65
 
â—
 
Smoke
 
at
 
least
 
[ADDRESS_659409]
 
6
 
months
 
â—
 
Own
 
an
 
iPhone
 
or
 
Android
 
smartphone
 
that
 
can
 
be
 
used
 
on
 
a
 
daily
 
basis
 
â—
 
Be
 
residents
 
of
 
Pennsylvania,
 
New
 
Jersey,
 
or
 
Delaware
 
â—
 
Read
 
and
 
speak
 
English
 
fluently
 
â—
 
Fully
 
vaccinated
 
against
 
COVID-19
 
Key
 
Exclusion
 
Criteria
  
for
 
remote
 
participation:
 
â—
 
Current
 
enrollment
 
or
 
plans
 
to
 
enroll
 
in
 
a
 
smoking
 
cessation
 
program
 
in
 
the
 
next
 
3
 
months
 
â—
 
Plan
 
to
 
use
 
nicotine
 
substitutes
 
or
 
smoking
 
cessation
 
treatments
 
in
 
the
 
next
 
3
 
months
 
â—
 
Urine
 
cotinine
 
concentration
 
below
 
200ng/mL
 
â—
 
Pregnancy
 
â—
 
Inability
 
or
 
refusal
 
to
 
complete
 
study
 
tasks
 
 
The
 
complete
 
list
 
of
 
study
 
inclusion
 
and
 
exclusion
 
criteria,
 
including
 
exclusion
 
criteria
 
for
 
the
 
fMRI
 
subset,
 
is
 
included
 
within
 
the
 
Characteristics
 
of
 
the
 
Study
 
Population
 
section
 
of
 
this
 
protocol.
 
V2025-06
 

 
Intervention
 
 
 
Random
 
assignment
 
of
 
retail
 
environment
 
(high
 
POSTM;
 
low
 
POSTM,
 
control
 
[no
 
store])
 
to
 
visit
 
5
 
times
 
per
 
week
 
during
 
the
 
4-week
 
intervention
 
period.
 
Statistical
 
Methodology
 
 
We
 
will
 
use
 
linear
 
regression
 
and
 
multilevel
 
models
 
(in
 
R)
 
to
 
test
 
our
 
hypotheses,
 
as
 
well
 
as
 
tools
 
from
 
nipype,
 
SPM,
 
and
 
fmriprep
 
to
 
process
 
and
 
model
 
fMRI
 
data.
 
 
 
Data
 
and
 
Safety
 
Monitoring
 
Plan
 
 
The
 
principal
 
investigator
 
[INVESTIGATOR_510050] ,
 
privacy ,
 
and
 
data
 
integrity
 
during
 
the
 
course
 
of
 
the
 
study .
 
In
 
addition,
 
we
 
will
 
provide
 
the
 
required
 
project
 
reports
 
to
 
the
 
sponsor .
 
 
â—
 
Background
 
and
 
Study
 
Rationale
 
 
This
 
document
 
is
 
a
 
protocol
 
for
 
a
 
human
 
research
 
study.
 
This
 
study
 
will
 
be
 
conducted
 
in
 
full
 
accordance
 
with
 
all
 
applicable
 
University
 
of
 
Pennsylvania
 
Research
 
Policies
 
and
 
Procedures
 
and
 
all
 
applicable
 
Federal
 
and
 
state
 
laws
 
and
 
regulations.
 
1
 
Introduction
 
 
Cigarette
 
smoking
 
is
 
the
 
leading
 
cause
 
of
 
preventable
 
death
 
and
 
illness
 
in
 
the
 
United
 
States
 
and
 
throughout
 
the
 
developed
 
world.
 
Recent
 
work
 
suggests
 
detrimental
 
links
 
between
 
exposure
 
to
 
point-of-sale
 
tobacco
 
marketing
 
(POSTM),
 
increases
 
in
 
cigarette
 
cravings,
 
and
 
the
 
failure
 
to
 
quit
 
smoking.
 
Understanding
 
how
 
individuals
 
are
 
influenced
 
by
 
[CONTACT_510069].
 
We
 
propose
 
to
 
use
 
an
 
innovative
 
set
 
of
 
methods
 
to
 
test
 
whether
 
repeated,
 
real-world
 
exposure
 
to
 
POSTM
 
affects
 
smoking
 
behavior,
 
and
 
whether
 
this
 
is
 
mediated
 
by
 
[CONTACT_510070].
 
Our
 
approach
 
combines
 
mobile-phone
 
based
 
geolocation
 
tracking,
 
ecological
 
momentary
 
assessment
 
(EMA),
 
and
 
functional
 
magnetic
 
resonance
 
imaging
 
(fMRI).
 
Research
 
using
 
geospatial
 
location
 
tracking
 
and
 
surveys
 
suggests
 
that
 
high
 
levels
 
of
 
POSTM
 
exposure
 
may
 
increase
 
craving;
 
however,
 
correlational
 
studies
 
preclude
 
causal
 
inferences
 
about
 
POSTM
 
effects.
 
Relatedly,
 
laboratory
 
studies
 
have
 
documented
 
neural
 
and
 
behavioral
 
reactivity
 
to
 
standardized
 
visual
 
smoking
 
cues,
 
such
 
as
 
photographs
 
of
 
cigarettes
 
in
 
an
 
ashtray,
 
but
 
the
 
brainâ€™s
 
response
 
to
 
naturalistic
 
POSTM
 
exposure
 
has
 
not
 
been
 
explored.
 
By
 
[CONTACT_510071],
 
and
 
causal
 
inferences
 
from
 
an
 
experimental
 
pre-post
 
design,
 
we
 
aim
 
to
 
significantly
 
advance
 
actionable
 
insight
 
about
 
POSTM
 
effects
 
in
 
cancer
 
control.
 
 
 
1.1
 
Background
 
and
 
Relevant
 
Literature
 
 
 
Summary:
 
The
 
tobacco
 
industry
 
has
 
come
 
to
 
rely
 
increasingly
 
on
 
point-of-sale
 
tobacco
  
marketing
 
(POST-M),
 
with
  
large
 
displays
 
near
 
cash
 
registers
 
in
 
retail
 
outlets
 
such
 
as
 
convenience
 
stores
 
and
 
gas
 
stations
 
[1].
 
Recent
  
work
 
utilizing
 
geospatial
 
location
 
tracking
 
has
 
found
 
that
 
smoking
 
V2025-[ADDRESS_659410]-M,
 
particularly
 
when
 
their
 
general
  
tobacco
 
craving
 
levels
 
are
 
otherwise
 
low
 
[2].
 
This
 
suggests
 
that
 
POST-M
 
exposure
 
may
 
increase
 
craving,
  
making
 
abstinence
 
more
 
difficult.
 
This
 
finding
 
converges
 
with
 
recent
 
survey
 
results
 
demonstrating
 
that
  
during
 
quit
 
attempts,
 
a
 
significant
 
percentage
 
of
 
smokers
 
experience
 
urges
 
to
 
purchase
 
cigarettes
 
when
  
exposed
 
to
 
POST-M,
 
and
 
feel
 
that
 
the
 
removal
 
of
 
POST-M
 
would
 
make
 
quitting
 
easier
 
[3].
 
These
 
reports
  
indicating
 
that
 
incidental
 
exposure
 
to
 
cigarette
 
cues
 
adversely
 
affects
 
smoking
 
abstinence
 
are
 
supported
  
by
 
[CONTACT_510072].
 
A
 
typi[INVESTIGATOR_510051],
 
such
 
as
 
a
 
hand
 
holding
 
a
 
cigarette,
 
followed
 
by
 
a
 
measurement
 
of
 
participants'
 
craving
  
intensity.
 
Smoking
 
abstinence
 
has
 
been
 
found
 
to
 
potentiate
  
self-reported
 
craving
 
in
 
response
 
to
 
cigarette
 
cues
 
[4-7,8],
  
suggesting
 
a
 
mechanism
 
for
 
the
 
finding
 
that
 
exposure
 
to
 
POST-M
 
during
 
a
 
quit
 
attempt
 
leads
 
to
 
poorer
  
outcomes.
 
No
 
studies,
 
however,
 
have
 
experimentally
 
manipulated
 
exposure
 
to
 
POST-M
 
cues
 
in
 
vivo.
 
To
 
this
 
end,
 
we
 
will
 
examine
 
whether
 
assigning
 
smokers
 
to
 
a
 
high
 
or
 
low
 
level
 
of
 
POST-M
 
exposure
 
as
 
part
 
of
 
their
 
daily
 
routine
 
affects
  
several
 
smoking
 
outcomes.
 
A
 
location
 
tracking
 
smartphone
 
application
 
(Google
 
Maps)
 
will
 
be
 
used
 
to
  
document
 
participantsâ€™
 
exposure
 
to
 
retail
 
outlets
 
and
 
link
 
each
 
person
 
to
 
the
 
retail
 
environment.
  
Measurements
 
will
 
assess
 
longitudinal
 
tobacco-use
 
patterns
 
and
 
perceptions
 
across
 
the
 
study
 
period,
 
as
  
well
 
as
 
changes
 
in
 
cravings.
 
If
 
it
 
is
 
the
 
case
 
that
 
low
 
POST-M
 
exposure
 
reduces
 
smoking,
 
this
 
emphasizes
 
the
 
importance
 
of
 
further
 
regulation
 
of
 
retail
 
advertising
 
for
  
tobacco.
 
 
 
In
 
addition
 
to
 
the
 
hypotheses
 
and
 
analysis
 
plans
 
described
 
here,
 
the
 
study
 
team
 
has
 
preregistered
 
additional
 
hypotheses
 
and
 
analysis
 
plans
 
which
 
are
 
not
 
the
 
focus
 
of
 
the
 
clinical
 
trial
 
component
 
of
 
the
 
study.
 
These
 
are
 
available
 
at
 
https://osf.io/kyb64/registrations
.
 
 
 
Background:
 
Tobacco
 
dependence
 
is
 
a
 
significant
 
public
 
health
 
problem.
 
Cigarette
 
smoking
 
is
 
the
 
leading
 
cause
 
of
 
preventable
 
death
 
and
 
illness
 
in
 
the
 
United
 
States
 
and
 
throughout
 
the
 
developed
 
world
[ADDRESS_659411]
 
frequently
 
diagnosed
 
cancers
 
and
 
other
 
leading
 
causes
 
of
 
death,
 
accounting
 
for
 
1
 
in
 
5
 
deaths
 
in
 
the
 
US
 
each
 
year
 
2,3
.
 
Due
 
to
 
restrictions
 
in
 
other
 
communication
 
outlets,
 
the
 
tobacco
 
industry
 
currently
 
concentrates
 
over
 
80%
 
of
 
its
 
$8.1
 
billion
 
annual
 
marketing
 
budget
 
on
 
retail
 
environments,
 
including
 
point-of-sale
 
tobacco
 
marketing
 
(POSTM)
4â€“8
.
 
Tobacco
 
advertising
 
and
 
products
 
are
 
placed
 
prominently
 
in
 
â€œpower
 
wallsâ€
 
near
 
or
 
behind
 
cash
 
registers
 
in
 
retail
 
outlets
 
like
 
convenience
 
stores
 
and
 
gas
 
stations
9,[ADDRESS_659412]
 
in
 
tobacco
 
control
 
and
 
cancer
 
prevention
 
research
 
worldwide,
 
and
 
has
 
led
 
to
 
recent
 
bans
 
of
 
POSTM
 
in
 
42%
 
of
 
countries
 
in
 
Europe
[ADDRESS_659413]
 
both
 
correlational
 
(Aims
 
1-2)
 
and
 
causal
 
(Aim
 
3)
 
pathways.
 
To
 
this
 
end,
 
we
 
propose
 
an
 
innovative
 
combination
 
of
 
geolocation
 
tracking
 
as
 
an
 
ecologically
 
valid,
 
objective
 
measure
 
of
 
real-world
 
POSTM
 
exposure
13,14
;
  
ecological
 
momentary
 
assessment
 
(EMA)
15
 
to
 
assess
 
real-time
 
behavior
 
and
 
craving;
 
and
 
functional
 
magnetic
 
resonance
 
imaging
 
(fMRI)
 
to
 
assess
 
neural
 
responses
 
to
 
cigarette
 
cues
16â€“18
.
 
Understanding
 
both
 
the
 
neural
 
(laboratory-based)
 
and
 
behavioral
 
(real-world)
 
consequences
 
of
 
exposure
 
to
 
POSTM
 
will
 
clarify
 
the
 
mechanisms
 
of
 
POSTM
 
impact,
 
and
 
ultimately
 
aid
 
in
 
the
 
design
 
of
 
more
 
effective
 
cancer
 
prevention
 
and
 
tobacco
 
regulatory
 
policies.
 
 
How
 
are
 
smokers
 
influenced
 
by
 
[CONTACT_2929]-of-sale
 
tobacco
 
marketing
 
(POSTM)?
 
Past
 
work
 
suggests
 
detrimental
 
relationships
 
between
 
exposure
 
to
 
POSTM
 
and
 
other
 
environmental
 
smoking
 
cues
 
and
 
smoking
 
behavior
 
in
 
individuals
 
(e.g.,
19,20
)
 
and
 
the
 
larger
 
population
 
(e.g.,
21
)
 
V2025-06
 

 
across
 
countries,
 
measures
 
and
 
study
 
designs
 
(for
 
a
 
review:
22
).
 
Within
 
current
 
and
 
recently
 
quit
 
smokers,
 
field
 
work
 
consistently
 
reports
 
associations
 
between
 
POSTM
 
exposure
 
in
 
naturalistic
 
settings,
 
and
 
increased
 
smoking
 
cravings,
 
purchase
 
urges,
 
and
 
impulse
 
purchases
23â€“28
.
 
The
 
density
 
of
 
POSTM
 
in
 
an
 
individualâ€™s
 
neighborhood,
 
a
 
proxy
 
for
 
exposure,
 
also
 
influences
 
smoking
 
behavior
29â€“33
;
 
for
 
example,
 
longitudinal
 
work
 
finds
 
that
 
smokers
 
are
 
more
 
likely
 
to
 
relapse
 
during
 
a
 
quit
 
attempt
 
if
 
they
 
live
 
near
 
a
 
POSTM
 
store
34
.
 
In
 
a
 
virtual
 
store
 
study,
 
enclosing
 
the
 
POSTM
 
display
 
reduced
 
smokersâ€™
 
purchase
 
attempts
 
and
 
urges
 
to
 
smoke
35
.
 
This
 
body
 
of
 
research
 
thus
 
suggests
 
that
 
further
 
regulation
 
of
 
POSTM
 
would
 
be
 
beneficial
 
from
 
a
 
cancer
 
control
 
perspective;
 
however,
 
causal
 
evidence
 
linking
 
longitudinal,
 
naturalistic
 
exposure
 
and
 
smoking
 
outcomes,
 
as
 
well
 
as
 
neural
 
evidence
 
supporting
 
the
 
mechanisms
 
of
 
cumulative
 
and
 
causal
 
effects,
 
would
 
substantially
 
bolster
 
science-based
 
policy
 
making.
 
 
The
 
significance
 
of
 
geolocation
 
tracking
 
and
 
ecological
 
momentary
 
assessment.
 
Geolocation
 
tracking
 
provides
 
the
 
unique
 
ability
 
to
 
objectively
 
and
 
unobtrusively
 
assess
 
participantsâ€™
 
exposure
 
to
 
POSTM
 
outlets.
 
The
 
recent
 
ubiquity
 
of
 
geolocation
 
tracking
 
built-in
 
to
 
smartphones
 
provides
 
the
 
opportunity
 
for
 
incorporating
 
this
 
methodology
 
into
 
experimental
 
designs
 
with
 
reduced
 
participant
 
burden.
 
This
 
is
 
a
 
significant
 
improvement
 
over
 
prior
 
POSTM
 
exposure
 
work,
 
which
 
is
 
limited
 
by
 
[CONTACT_510073]-reports
 
of
 
the
 
timing
 
and
 
degree
 
of
 
POSTM
 
exposure,
 
or
 
by
 
[CONTACT_510074],
 
non-representative
 
exposures.
 
In
 
PA,
 
DE,
 
and
 
NJ,
 
where
 
data
 
collection
 
will
 
take
 
place,
 
obtaining
 
a
 
local
 
cigarette
 
dealer
 
license
 
is
 
mandatory
 
for
 
cigarette
 
retailers
36
 
and
 
listings
 
of
 
licensed
 
outlets
 
are
 
publicly
 
available
 
and
 
updated
 
monthly
37
.
 
Layering
 
smokersâ€™
 
geolocation
 
tracks
 
onto
 
maps
 
of
 
tobacco
 
retail
 
outlets
 
allows
 
objective
 
quantification
 
of
 
an
 
individualâ€™s
 
exposure
 
to
 
POSTM
 
in
 
their
 
natural
 
environment.
 
38
.
 
In
 
parallel
 
with
 
geolocation
 
tracking,
 
we
 
will
 
sample
 
participantsâ€™
 
behaviors
 
and
 
craving
 
throughout
 
each
 
day
 
using
 
EMA,
 
to
 
capture
 
time-sensitive
 
fluctuations
 
in
 
a
 
representative
 
manner
15
.
 
EMA
 
optimally
 
complements
 
the
 
naturalistic
 
geolocation
 
tracking
 
data
 
by
 
[CONTACT_510075]â€™
 
location
 
history
 
with
 
reports
 
indicating
 
natural
 
smoking
 
behavior
 
and
 
craving
 
on
 
a
 
moment-to-moment
 
basis.
 
Thus,
 
this
 
project
 
will
 
link
 
individualsâ€™
 
smoking
 
cravings
 
and
 
behavior
 
to
 
the
 
POSTM
 
environment
 
in
 
both
 
time
 
and
 
location.
 
Our
 
teamâ€™s
 
expertise
 
with
 
mobile
 
device-based
 
EMA
 
collection
41,[ADDRESS_659414]
 
to
 
many
 
other
 
addictive
 
substances,
 
advertising
 
for
 
cigarettes
 
is
 
professionally
 
produced,
 
legal,
 
and
 
prevalent
 
in
 
smokersâ€™
 
natural
 
environments.
 
Neural
 
cue
 
reactivity
 
effects
 
have
 
been
 
generalized
 
from
 
completely
 
standardized
 
cues
 
to
 
more
 
naturalistic
 
pi[INVESTIGATOR_510052],
 
such
 
that
 
exposure
 
to
 
photographs
 
of
 
places
 
where
 
participants
 
often
 
smoke
 
(e.g.,
 
oneâ€™s
 
home)
 
evokes
 
stronger
 
neural
 
and
 
behavioral
 
craving
 
responses
 
than
 
exposure
 
to
 
generic
 
environmental
 
photographs
 
(e.g.,
 
an
 
unfamiliar
 
bus
 
stop)
18,48,49
;
 
however,
 
the
 
generalizability
 
of
 
such
 
effects
 
to
 
POSTM
 
cues
 
and
 
complex
 
retail
 
environments
 
has
 
not
 
been
 
tested.
 
We
 
will
 
test
 
whether
 
baseline
 
exposure
 
to
 
photographs
 
of
 
POSTM
 
elicits
 
activation
 
in
 
the
 
V2025-[ADDRESS_659415]
 
smoking
 
cues
16
 
and
 
mediated
 
messages
 
such
 
as
 
marketing
 
materials
50â€“[ADDRESS_659416]
 
the
 
generalizability
 
and
 
predictive
 
validity
 
of
 
laboratory-based
 
neural
 
effects
 
to
 
real-world
 
behaviors
 
51â€“69
.
 
This
 
work
 
has
 
shown
 
that
 
neural
 
reactivity
 
to
 
persuasive
 
messaging
 
inside
 
the
 
fMRI
 
scanner
 
reliably
 
predicts
 
health
 
behaviors,
 
including
 
reductions
 
in
 
smoking
 
and
 
sedentary
 
behavior,
 
above
 
and
 
beyond
 
the
 
predictive
 
capacity
 
of
 
commonly
 
used
 
self-reports
 
51,59,60,64,65,70â€“[ADDRESS_659417]
 
extant
 
field
 
work
 
focused
 
on
 
POSTM,
 
despi[INVESTIGATOR_510053],
 
has
 
been
 
correlational,
 
with
 
a
 
few
 
notable
 
exceptions.
 
For
 
example,
 
Shadel
 
et
 
al
 
created
 
an
 
experimental
 
convenience
 
store,
 
and
 
found
 
that
 
removal
 
of
 
the
 
POSTM
 
power
 
wall
 
reduced
 
susceptibility
 
to
 
future
 
cigarette
 
smoking
 
in
 
adolescents
78
.
 
The
 
current
 
study
 
proposes
 
to
 
significantly
 
extend
 
these
 
findings
 
by
 
[CONTACT_510076]â€™
 
real-world,
 
daily
 
POSTM
 
exposure
 
over
 
the
 
course
 
of
 
one
 
month,
 
rather
 
than
 
assessing
 
the
 
impact
 
of
 
a
 
single
 
exposure
 
in
 
one
 
experimental
 
session.
 
After
 
an
 
observation
 
period
 
of
 
geolocation
 
tracking
 
and
 
EMA,
 
individuals
 
will
 
be
 
randomly
 
assigned
 
to
 
1
 
of
 
3
 
groups.
 
Two
 
groups
 
enter
 
and
 
make
 
small,
 
non-tobacco
 
purchases
 
at
 
a
 
store
 
which
 
displays
 
POSTM
 
(tobacco
 
retailer
 
condition)
 
or
 
a
 
store
 
that
 
displays
 
pro-cessation
 
messaging
 
(nontobacco
 
retailer
 
condition).
 
Approaching
 
the
 
register
 
for
 
this
 
purchase
 
constitutes
 
an
 
exposure
 
to
 
POSTM
 
(tobacco
 
retailer
 
condition)
 
or
 
pro-cessation
 
marketing
 
(nontobacco
 
retailer
 
condition).
 
A
 
third
 
group
 
receives
 
no
 
instruction
 
to
 
change
 
their
 
routine
 
exposure
 
to
 
POSTM.
 
 
 
 
 
2
 
Study
 
Objectives
 
2.1
 
Primary
 
Objective
 
 
The
 
primary
 
objectives
 
are
 
to
 
examine
 
the
 
relationships
 
between
 
smoking
 
behavior,
 
cigarette
 
cravings,
 
and
 
exposure
 
to
 
point-of-sale
 
tobacco
 
marketing.
 
We
 
will
 
examine
 
whether
 
experimental
 
group
 
assignment
 
affects
 
cigarette
 
cravings
 
and
 
cigarette
 
consumption
 
during
 
the
 
intervention
 
period
 
relative
 
to
 
the
 
baseline.
 
For
 
the
 
subset
 
of
 
participants
 
who
 
undergo
 
fMRI
 
scanning,
 
we
 
will
 
compare
 
craving
 
ratings
 
and
 
brain
 
activity
 
during
 
different
 
task
 
conditions.
 
 
V2025-06
 

 
3
 
Investigational
 
Plan
 
 
3.1
 
General
 
Design
 
Study
 
Type:
 
Interventional
 
Primary
 
Purpose:
 
Other
 
Study
 
Phase:
 
N/A
 
Interventional
 
Study
 
Model:
 
Parallel
 
Assignment
 
Random
 
assignment
 
of
 
retail
 
environment
 
(tobacco
 
retailer,
 
non-tobacco
 
retailer,
 
no
 
store)
 
to
 
visit
 
5
 
times
 
per
 
week
 
during
 
the
 
4-week
 
intervention
 
period
 
 
Number
 
of
 
Arms:
 
3
 
Masking:
 
Single
 
(Investigator)
 
Investigator
 
will
 
not
 
know
 
the
 
condition
 
assignment
 
of
 
individual
 
participants
 
unless
 
reassessment
 
is
 
triggered
 
by
 
[CONTACT_510077][INVESTIGATOR_510054].
 
 
Allocation:
 
Randomized
 
Enrollment:
 
343
 
[Actual]
 
 
3.2
 
Allocation
 
to
 
Interventional
 
Group
 
 
 
Participants
 
who
 
completed
 
the
 
required
 
tasks
 
during
 
the
 
baseline
 
period
 
were
 
randomized
 
within
 
blocks
 
[blocked
 
by
 
[CONTACT_547]
 
(male,
 
female,
 
other)
 
and
 
smoking
 
level
 
(high,
 
low;
 
high
 
was
 
20
 
cigarettes
 
or
 
greater
 
per
 
day)].
 
At
 
the
 
beginning
 
of
 
data
 
collection,
 
condition
 
assignment
 
was
 
fully
 
random;
 
blocked-randomization
 
was
 
implemented
 
part-way
 
through
 
the
 
study
 
on
 
12/01/2022.
 
3.3
 
Study
 
Measures
 
 
 
SCREEN
 
 
A
 
SCREEN
 
 
B
 
INITIAL
 
CALL
 
SURVEY
 
1
 
BASELINE
 
SURVEY
 
2
 
INTERVENTIO 
N
 
SURVEY
 
3
 
FMRI
 
Measures
 
 
 
 
Day
 
0
 
Day
 
1
 
â€“
 
15
 
Day
 
15
 
Day
 
15
 
â€“
 
[ADDRESS_659418]
 
(photo)
 
 
X
 
 
 
 
 
 
 
 
Location
 
tracking
 
(timeline
 
export)
 
 
X
 
 
 
 
X
 
 
 
 
Urine
 
cotinine
 
test
 
(photo)
 
 
 
 
X
 
 
 
 
 
X
 
Receipts
 
(photos)
 
 
 
 
 
 
 
20X
 
 
 
Screening
 
and
 
Covariates
 
 
 
 
 
 
 
 
 
 
V2025-06
 

 
Eligibility
 
screening
 
X
 
X
 
 
 
 
 
 
 
 
Smoking
 
behavior
 
survey
 
 
 
 
X
 
 
X
 
 
X
 
1
 
item
 
Nicotine
 
dependence
 
survey
 
(FTND)
 
 
 
 
X
 
 
X
 
 
X
 
X
 
Smoking
 
habits
 
survey
 
 
 
 
X
 
 
 
 
X
 
 
Smoking
 
cessation
 
intentions
 
survey
 
 
 
 
X
 
 
 
 
X
 
 
Smoking
 
info
 
exposure
 
questionnaire
 
 
 
 
X
 
 
X
 
 
X
 
 
Smoking
 
beliefs
 
survey
 
 
 
 
X
 
 
 
 
X
 
 
Smoking
 
attitudes
 
survey
 
 
 
 
X
 
 
 
 
X
 
 
Social
 
smoking
 
norms
 
survey
 
 
 
 
X
 
 
 
 
X
 
 
Smoking
 
motivation
 
survey
 
 
 
 
X
 
 
 
 
 
 
Tobacco
 
policy
 
support
 
questionnaire
 
 
 
 
 
X
 
 
 
 
X
 
 
Social
 
interactions
 
&
 
smoking
 
survey
 
 
 
 
 
 
X
 
(weekly
 
survey)
 
4X
 
(weekly
 
survey)
 
 
 
Demographics
 
survey
 
 
 
 
 
X
 
 
 
 
 
 
Stressful
 
Life
 
Experiences
 
Inventory
 
 
 
 
 
 
 
X
 
 
 
 
Microaggression 
s
 
survey
 
 
 
 
X
 
 
X
 
(weekly
 
survey)
 
4X
 
(weekly
 
survey)
 
X
 
 
Purpose
 
in
 
life
 
survey
 
 
 
 
X
 
1
 
item
 
daily
 
 
1
 
item
 
daily
 
 
 
Smoker
 
self-concept
 
survey
 
 
 
 
X
 
 
 
 
X
 
 
V2025-06
 

 
Perceived
 
stress
 
scale
 
 
 
 
X
 
 
 
 
X
 
 
CES-D
 
Depression
 
scale
 
 
 
 
X
 
 
 
 
X
 
 
Code
 
switching
 
survey
 
 
 
 
X
 
 
 
 
X
 
 
Mindfulness
 
(MAAS)
 
 
 
 
 
 
 
 
 
X
 
Impulsiveness
 
(BIS-11)
 
 
 
 
 
 
 
 
 
X
 
Alcohol
 
consumption
 
 
 
 
 
 
 
 
 
X
 
Outcomes
 
 
 
 
 
 
 
 
 
 
Cigarette
 
consumption-
 
self-report
 
 
 
 
X
 
 
X
 
 
X
 
 
EMA
 
text
 
surveys
 
-
 
smoking
 
and
 
craving
 
 
 
 
 
 
X
 
 
X
 
 
 
Cue
 
reactivity
 
task
 
 
 
 
 
 
X
 
 
X
 
X
 
 
 
 
 
3.4
 
Study
 
Endpoints
 
 
3.4.1
 
Primary
 
Study
 
Endpoint
 
 
 
The
 
primary
 
endpoints
 
will
 
be
 
cigarette
 
smoking
 
and
 
craving
 
at
 
the
 
end
 
of
 
the
 
intervention
 
period,
 
measured
 
through
 
EMA
 
multiple
 
times
 
daily.
 
The
 
primary
 
endpoints
 
for
 
the
 
fMRI
 
scan
 
session
 
will
 
be
 
measured
 
through
 
fMRI
 
scanning
 
(brain
 
activity).
 
3.4.[ADDRESS_659419]
 
6
 
months,
 
are
 
smartphone
 
users,
 
and
 
live
 
in
 
PA/NJ/DE.
 
4.1
 
Duration
 
of
 
Study
 
Participation
 
 
The
 
target
 
behaviors
 
(smoking
 
frequency,
 
cravings
 
for
 
cigarettes)
 
will
 
be
 
assessed
 
for
 
an
 
approximately
 
2
 
week
 
baseline
 
period
 
and
 
for
 
an
 
approximately
 
4
 
week
 
intervention
 
period.
 
Thus,
 
total
 
study
 
participation
 
is
 
expected
 
to
 
be
 
approximately
 
6
 
weeks
 
of
 
active
 
participation,
 
with
 
possible
 
breaks
 
in
 
between
 
the
 
baseline
 
and
 
intervention
 
periods.
 
Total
 
duration
 
of
 
V2025-06
 

 
participation
 
will
 
thus
 
be
 
approximately
 
2
 
months,
 
with
 
some
 
exceptions
 
(such
 
as
 
pauses
 
in
 
active
 
participation
 
because
 
of
 
the
 
Universityâ€™s
 
special
 
winter
 
vacation,
 
or
 
as
 
requested
 
by
 
[CONTACT_510078]).
 
A
 
subset
 
of
 
participants
 
will
 
be
 
invited
 
to
 
complete
 
an
 
optional
 
fMRI
 
scan
 
after
 
their
 
final
 
online
 
session;
 
flexibility
 
will
 
be
 
allowed
 
in
 
the
 
timing
 
of
 
the
 
scan
 
session,
 
which
 
can
 
be
 
as
 
long
 
as
 
6
 
months
 
after
 
the
 
final
 
online
 
session.
 
This
 
subset
 
of
 
participants
 
will
 
participate
 
for
 
a
 
longer
 
duration
 
(total
 
duration
 
of
 
participation
 
can
 
be
 
up
 
to
 
8
 
months
 
[2
 
months
 
of
 
active
 
participation,
 
with
 
a
 
scan
 
session
 
up
 
to
 
6
 
months
 
later].
 
4.2
 
Total
 
Number
 
of
 
Subjects
 
and
 
Sites
 
 
 
Our
 
initial
 
recruitment
 
plan
 
specified
 
that
 
â€œRecruitment
 
will
 
end
 
when
 
approximately
 
[ADDRESS_659420]
 
been
 
enrolled.
 
It
 
is
 
expected
 
that
 
400
 
enrolled
 
participants
 
will
 
produce
 
180
 
evaluable
 
subjects
 
after
 
attrition
 
and
 
data
 
issues.
 
Penn
 
is
 
the
 
only
 
site.â€
 
See
 
6.1
 
for
 
final
 
plan,
 
adjusting
 
for
 
COVID
 
and
 
other
 
constraints.
 
4.3
 
Inclusion
 
Criteria
 
 
â—
 
Be
 
between
 
the
 
ages
 
of
  
21-65
 
â—
 
Smoke
 
at
 
least
 
[ADDRESS_659421]
 
6
 
months
 
â—
 
Own
 
an
 
iPhone
 
or
 
Android
 
smartphone
 
that
 
can
 
be
 
used
 
on
 
a
 
daily
 
basis
 
â—
 
Be
 
residents
 
of
 
Pennsylvania,
 
New
 
Jersey,
 
or
 
Delaware
 
â—
 
Read
 
and
 
speak
 
English
 
fluently
 
â—
 
Fully
 
vaccinated
 
against
 
COVID-19
 
4.4
 
Exclusion
 
Criteria
 
â—
 
Current
 
enrollment
 
or
 
plans
 
to
 
enroll
 
in
 
a
 
smoking
 
cessation
 
program
 
in
 
the
 
next
 
3
 
months
  
 
â—
 
Plan
 
to
 
use
 
nicotine
 
substitutes
 
or
 
smoking
 
cessation
 
treatments
 
in
 
the
 
next
 
3
 
months
  
 
â—
 
Pregnancy
  
 
â—
 
Refusal
 
to
 
install
 
Google
 
Maps
 
or
 
LifeData
 
applications
 
on
 
mobile
 
phone
 
 
â—
 
Inability
 
or
 
refusal
 
to
 
upload
 
Google
 
Timeline
 
data
 
after
 
receiving
 
instructions
 
and
 
guidance
 
during
 
or
 
after
 
the
 
initial
 
intake
 
call
  
 
â—
 
During
 
the
 
ï¬rst
 
two
 
weeks
 
of
 
the
 
study,
 
failure
 
to
 
complete
 
the
 
study
 
tasks
 
(response
 
to
 
at
 
least
 
75%
 
of
 
the
 
brief
 
EMA
 
survey
 
questions)
 
 
â—
 
Urine
 
cotinine
 
testing
 
at
 
Session
 
1
 
indicates
 
a
 
non-smoker
 
level
 
of
 
cotinine
 
 
â—
 
The
 
phones
 
of
 
potential
 
participants
 
will
 
be
 
assessed
 
by
 
[CONTACT_510079]
 
a
 
phone
 
call
 
used
 
to
 
invite
 
eligible
 
participants
 
who
 
completed
 
Screen
 
A
 
to
 
participate
 
in
 
the
 
study.
 
Speciï¬cally,
 
recruiters
 
will
 
assess
 
whether
 
phones'
 
functionality
 
allows
 
easy
 
reception
 
and
 
sending
 
of
 
text
 
messages,
 
the
 
use
 
of
 
the
 
geolocation
 
tracking
 
and
 
LifeData
 
applications
 
and
 
whether
 
phones
 
have
 
an
 
adequate
 
battery
 
life
 
to
 
allow
 
participants
 
to
 
fulï¬ll
 
study
 
requirements.
 
 
â—
 
Inability
 
to
 
provide
 
informed
 
consent
 
or
 
complete
 
any
 
of
 
the
 
study
 
tasks
 
as
 
determined
 
by
 
[CONTACT_95451]
 
[INVESTIGATOR_1238]/or
 
Study
 
Physician.
  
 
â—
 
Any
 
physical
 
or
 
visual
 
impairment
 
that
 
may
 
prevent
 
the
 
individual
 
from
 
using
 
a
 
computer
 
keyboard
 
or
 
completing
 
any
 
study
 
tasks.
 
Additional
 
criteria
 
for
 
fMRI
 
component:
 
â—
 
Demonstrate
 
urine
 
cotinine
 
concentration
 
below
 
200
 
ng/mL
 
at
 
scanning
 
session
 
â—
 
Currently
 
or
 
recently
 
(within
 
the
 
last
 
5
 
years)
 
receiving
 
medical
 
treatment
 
for
 
substance
 
abuse
 
(e.g.,
 
alcohol,
 
opi[INVESTIGATOR_2438],
 
cocaine,
 
marijuana,
 
or
 
stimulants).
 
Treatment
 
of
 
substance
 
use
 
disorders
 
that
 
occurred
 
greater
 
than
 
5
 
years
 
prior
 
to
 
study
 
participation
 
is
 
acceptable
 
if
 
participants
 
are
 
in
 
stable
 
condition
 
V2025-06
 

 
â—
 
Report
 
consuming
 
any
 
of
 
the
 
following
 
drugs
 
within
 
the
 
past
 
two
 
weeks
 
or
 
indicate
 
plans
 
to
 
do
 
so
 
within
 
the
 
coming
 
6
 
weeks
 
during
 
the
 
screening
 
call:
 
Benzodiazepi[INVESTIGATOR_1651],
 
Amphetamines,
 
Methamphetamines,
 
Cocaine,
 
MDMA,
 
Methadone,
 
Barbiturates,
 
PCP,
 
Heroin,
 
Oxycodone,
 
Opi[INVESTIGATOR_858]
 
(e.g.,
 
morphine,
 
heroin),
 
Buprenorphine
 
 
â—
 
Test
 
positive
 
for
 
any
 
of
 
the
 
above
 
drugs
 
at
 
the
 
scan
 
appointment
 
â—
 
Schizophrenia
 
or
 
psychosis,
 
regardless
 
of
 
treatment
 
status.
 
â—
 
History
 
of
 
stroke
 
or
 
other
 
neurological
 
disorder
 
likely
 
to
 
affect
 
cognition
 
 
â—
 
Psychiatric
 
hospi[INVESTIGATOR_510055]
 
 
â—
 
Propensity
 
to
 
experience
 
claustrophobia
 
 
â—
 
Ferromagnetic
 
metal
 
in
 
the
 
body,
 
including
 
anything
 
that
 
might
 
set
 
off
 
a
 
metal
 
detector.
 
Examples
 
include
 
bullet
 
shrapnel,
 
metal
 
shavings
 
(e.g.,
 
from
 
welding
 
without
 
protection),
 
or
 
any
 
implant
 
that
 
may
 
be
 
attracted
 
to
 
or
 
damaged
 
by
 
[CONTACT_510080].
 
Dental
 
fillings
 
are
 
generally
 
acceptable.
 
 
â—
 
Metal
 
in
 
the
 
body
 
of
 
an
 
unverifiable
 
origin.
 
 
â—
 
Non-removable
 
pi[INVESTIGATOR_2982].
 
 
â—
 
Non-removable
 
retainers
 
or
 
other
 
dental
 
work
 
not
 
compatible
 
with
 
fMRI.
 
 
â—
 
Any
 
orthopedic
 
implant
 
above
 
the
 
neck.
 
 
â—
 
Due
 
to
 
constraints
 
of
 
the
 
fMRI
 
scanner,
 
participants
 
whose
 
weight
 
exceeds
 
350
 
pounds
 
also
 
will
 
be
 
excluded.
 
The
 
size
 
of
 
the
 
scanner
 
will
 
be
 
discussed
 
with
 
all
 
participants
 
during
 
the
 
consent
 
addendum
 
procedure.
 
 
â—
 
Any
 
medical
 
condition
 
or
 
concomitant
 
medication
 
that
 
could
 
compromise
 
participant
 
safety
 
or
 
treatment,
 
as
 
determined
 
by
 
[CONTACT_95451]
 
[INVESTIGATOR_1238]/or
 
Study
 
Physician.
 
â—
 
Unable
 
to
 
schedule
 
a
 
scan
 
within
 
[ADDRESS_659422]
 
recruitment
 
may
 
occur
 
through
 
newsletters,
 
fliers,
 
online
 
ads/posts
 
(e.g.,
 
Craigslist,
 
Facebook,
 
Instagram),
 
newspaper
 
listings,
 
and/or
 
ads
 
on
 
TV
 
(or
 
streaming
 
media
 
services).
 
Recruitment
 
materials
 
may
 
be
 
posted
 
by
 
[CONTACT_510081].
 
We
 
will
 
also
 
collaborate
 
with
 
another
 
smoking
 
research
 
group
 
at
 
the
 
University
 
of
 
Pennsylvania
 
which
 
has
 
IRB
 
approval
 
for
 
passing
 
on
 
contact
 
[CONTACT_510082]. Only
 
participants
 
who
 
have
 
indicated
 
that
 
they
 
are
 
interested
 
in
 
being
 
contact[CONTACT_510083].
 
Upon
 
contact,
 
it
 
will
 
be
 
made
 
clear
 
to
 
participants
 
that
 
there
 
is
 
a
 
possibility
 
for
 
them
 
to
 
participate
 
in
 
the
 
study
 
and
 
they
 
will
 
be
 
provided
 
with
 
IRB-approved
 
recruitment
 
materials
 
such
 
as
 
flyers,
 
text,
 
and/
 
or
 
oral
 
information
 
about
 
the
 
study,
 
depending
 
on
 
the
 
mode
 
of
 
contact.
 
All
 
recruitment
 
material
 
will
 
include
 
links
 
(e.g.,
 
URLs,
 
QR
 
codes)
 
directing
 
potential
 
participants
 
to
 
the
 
screening
 
survey
 
(Screen
 
A).
 
The
 
study
 
email
 
address
 
and/or
 
phone
 
number
 
may
 
be
 
included,
 
depending
 
on
 
the
 
recruitment
 
medium.
 
Interested
 
individuals
 
will
 
complete
 
Screen
 
A
 
on
 
their
 
own
 
device
 
at
 
a
 
time
 
that
 
is
 
convenient
 
to
 
them.
 
 
 
Vulnerable
 
Populations:
 
 
 
Not
 
applicable
 
[ADDRESS_659423]
 
in
 
the
 
study
 
by
 
[CONTACT_510084]
 
(Screen
 
A)
 
where
 
they
 
answer
 
questions
 
relevant
 
to
 
their
 
eligibility
 
for
 
the
 
study
 
and
 
provide
 
their
 
contact
 
[CONTACT_3031].
 
Screen
 
A
 
will
 
also
 
include
 
a
 
question
 
that
 
asks
 
about
 
the
 
participantsâ€™
 
interest
 
in
 
receiving
 
information
 
on
 
opportunities
 
to
 
participate
 
in
 
other
 
remote
 
and/or
 
in-person
 
studies.
 
 
â—
 
Screen
 
A
 
will
 
be
 
administered
 
online
 
via
 
RedCap
 
or
 
BuildClinical
 
and
 
is
 
estimated
 
to
 
take
 
less
 
than
 
5
 
minutes
 
to
 
complete.
 
 
â—
 
[Note:
 
If
 
oneâ€™s
 
screening
 
survey
 
responses
 
indicate
 
that
 
they
 
are
 
not
 
eligible
 
to
 
participate
 
in
 
this
 
study,
 
they
 
will
 
receive
 
an
 
email
 
informing
 
them
 
of
 
this.]
 
 
â—
 
[Note:
 
If
 
one's
 
screening
 
survey
 
responses
 
indicate
 
that
 
they
 
are
 
interested
 
in,
 
and
 
potentially
 
eligible
 
for,
 
the
 
in-person
 
version
 
of
 
this
 
study
 
(protocol
 
822815),
 
they
 
may
 
be
 
provided
 
a
 
link
 
to
 
that
 
studyâ€™s
 
screening
 
survey
 
and
 
will
 
be
 
filtered
 
through
 
the
 
process
 
outlined
 
in
 
the
 
822815
 
protocol.
 
If
 
they
 
are
 
then
 
found
 
to
 
be
 
ineligible
 
for
 
the
 
in-person
 
study,
 
they
 
may
 
be
 
redirected
 
to
 
this
 
remote
 
study.]
 
 
 
Survey
 
respondents
 
who
 
are
 
potentially
 
eligible
 
to
 
participate
 
in
 
the
 
remote
 
study
 
will
 
be
 
emailed
 
and/or
 
texted
 
a
 
link
 
to
 
Calendly
 
(appointment
 
booking
 
system)
 
to
 
allow
 
participants
 
to
 
sign
 
up
 
for
 
a
 
time
 
for
 
an
 
initial
 
phone
 
call
 
to
 
find
 
out
 
more
 
about
 
the
 
study.
 
 
 
5.1.2
 
Initial
 
Call
 
During
 
the
 
initial
 
call,
 
participants
 
will
 
be
 
informed
 
about
 
the
 
study,
 
including
 
the
 
risks
 
and
 
benefits
 
of
 
participation,
 
and
 
will
 
be
 
given
 
the
 
opportunity
 
to
 
ask
 
questions.
 
Eligibility
 
criteria
 
will
 
be
 
confirmed
 
on
 
this
 
call
 
as
 
needed.
 
 
â—
 
The
 
initial
 
call
 
will
 
be
 
conducted
 
over
 
the
 
phone
 
(Google
 
Voice)
 
and
 
is
 
expected
 
to
 
take
 
approximately
 
[ADDRESS_659424].
 
The
 
instructions
 
will
 
then
 
guide
 
them
 
through
 
downloading
 
and/or
 
setting
 
up
 
Google
 
Maps
 
on
 
their
 
phone,
 
then
 
exporting
 
and
 
uploading
 
their
 
Google
 
timeline
 
(location
 
history)
 
data.
 
 
â—
 
Screen
 
B
 
will
 
be
 
administered
 
online
 
using
 
RedCap
 
and
 
Qualtrics
 
(with
 
Penn
 
Box
 
as
 
a
 
back-up
 
method
 
for
 
submitting
 
location
 
data,
 
if
 
needed).
 
The
 
screen
 
is
 
expected
 
to
 
take
 
5
 
-
 
15
 
minutes
 
of
 
active
 
participation,
 
which
 
excludes
 
the
 
passive
 
time
 
(when
 
participants
 
are
 
not
 
asked
 
to
 
do
 
anything)
 
while
 
Google
 
is
 
compi[INVESTIGATOR_510056].
 
â—
 
Potential
 
participants
 
who
 
have
 
difficulty
 
with
 
the
 
Google
 
Maps
 
set-up
 
or
 
timeline
 
export
 
will
 
be
 
able
 
to
 
sign
 
up
 
for
 
an
 
additional
 
phone/video
 
call
 
at
 
a
 
later
 
time
 
to
 
receive
 
help
 
from
 
a
 
researcher.
 
 
 
V2025-06
 

 
Researchers
 
will
 
then
 
confirm
 
A)
 
that
 
potential
 
participants
 
live
 
in
 
the
 
study
 
area
 
(PA,
 
NJ,
 
or
 
DE)
 
using
 
the
 
uploaded
 
timeline
 
data
 
and
 
shippi[INVESTIGATOR_510057]
 
B)
 
that
 
the
 
potential
 
participant
 
is
 
fully
 
vaccinated
 
against
 
COVID-19,
 
both
 
of
 
which
 
are
 
required
 
to
 
be
 
eligible
 
to
 
participate
 
in
 
this
 
study.
 
 
â—
 
[Note:
 
Those
 
who
 
are
 
unable/unwilling
 
to
 
complete
 
any
 
component
 
of
 
Screen
 
B,
 
live
 
outside
 
of
 
the
 
specified
 
study
 
area,
 
or
 
are
 
not
 
fully
 
vaccinated
 
will
 
be
 
ineligible
 
for
 
this
 
study
 
and
 
will
 
not
 
be
 
given
 
the
 
opportunity
 
to
 
enroll.
 
The
 
team
 
will
 
inform
 
them
 
of
 
their
 
ineligibility,
 
delete
 
their
 
geolocation
 
data,
 
and
 
provide
 
them
 
with
 
instructions
 
for
 
turning
 
off
 
Google
 
Timeline
 
and
 
uninstalling
 
Google
 
Maps.]
 
 
â—
 
[Note:
 
If
 
potential
 
or
 
enrolled
 
participants
 
are
 
no
 
longer
 
interested
 
in
 
enrolling
 
in
 
the
 
study
 
at
 
any
 
point
 
during
 
or
 
after
 
the
 
Google
 
Maps
 
set
 
up,
 
they
 
will
 
be
 
provided
 
with
 
instructions
 
for
 
turning
 
off
 
Google
 
Timeline
 
and
 
uninstalling
 
the
 
app.]
 
5.1.[ADDRESS_659425],
 
KN95/KF94
 
or
 
N95
 
masks,
 
and
 
a
 
Greenphire
 
Clincard.
 
Upon
 
receipt
 
of
 
the
 
study
 
materials,
 
participants
 
will
 
be
 
given
 
instructions
 
to
 
enroll
 
in
 
the
 
study
 
and
 
begin
 
their
 
participation
 
by
 
[CONTACT_510085]
 
1.
 
 
5.2
 
Study
 
Observational
 
Phase
 
 
5.2.1
 
Online
 
Session
 
1
 
(S1)
 
In
 
Session
 
1,
 
participants
 
will
 
read
 
through
 
the
 
consent
 
form
 
and
 
provide
 
electronic
 
consent
 
via
 
RedCap
 
to
 
participate
 
in
 
the
 
full
 
study
 
and
 
provide
 
information
 
required
 
for
 
payment
 
(legal
 
name,
 
date
 
of
 
birth,
 
and
 
Social
 
Security
 
number).
 
Participants
 
will
 
then
 
follow
 
the
 
survey
 
instructions
 
to:
 
complete
 
physiological
 
measurements
 
(urine
 
cotinine)
 
and
 
self-report
 
measures;
 
receive
 
instructions
 
for
 
the
 
Baseline
 
period
 
EMA
 
task
 
and
 
answer
 
questions
 
assessing
 
their
 
comprehension
 
of
 
the
 
task;
 
and
 
install,
 
set
 
up,
 
and
 
practice
 
using
 
RealLife
 
Exp
 
(the
 
EMA
 
app)
 
on
 
their
 
smartphone.
 
â—
 
Session
 
1
 
will
 
be
 
administered
 
over
 
RedCap
 
and
 
Qualtrics,
 
and
 
is
 
expected
 
to
 
take
 
30-60
 
minutes.
 
â—
 
If
 
a
 
participantâ€™s
 
urine
 
cotinine
 
test
 
result
 
is
 
not
 
above
 
the
 
threshold
 
required
 
for
 
eligibility,
 
the
 
participant
 
will
 
be
 
excluded
 
from
 
continuing
 
in
 
the
 
study.
 
5.2.[ADDRESS_659426]
 
for
 
14
 
days.
 
During
 
the
 
baseline
 
period,
 
participants
 
will
 
complete
 
EMA
 
and
 
location
 
tracking.
 
 
â—
 
Participants
 
will
 
be
 
excluded
 
for
 
non-compliance
 
at
 
the
 
end
 
of
 
the
 
baseline
 
period
 
if
 
they
 
have
 
not
 
responded
 
to
 
at
 
least
 
75%
 
of
 
EMA
 
prompts.
 
 
â—
 
Following
 
the
 
baseline
 
period,
 
participants
 
will
 
be
 
assigned
 
to
 
an
 
experimental
 
condition.
  
 
 
 
5.3
 
Study
 
Interventional
 
Phase
 
5.3.1
 
Online
 
Session
 
2
 
Participants
 
will
 
be
 
invited
 
to
 
complete
 
Session
 
2
 
online
 
after
 
completing
 
the
 
baseline
 
observational
 
period.
 
They
 
are
 
encouraged
 
to
 
complete
 
the
 
session
 
within
 
4
 
days
 
and
 
no
 
longer
 
than
 
1
 
week
 
(with
 
possibility
 
for
 
exceptions
 
at
 
experimenters
 
discretion)
 
after
 
receiving
 
the
 
invitation.
 
Participants
 
complete
 
self-report
 
measures;
 
an
 
image
 
rating
 
task;
 
geolocation
 
data
 
V2025-06
 

 
export
 
and
 
upload;
 
EMA
 
setup
 
and
 
practice;
 
and
 
instructions
 
and
 
practice
 
for
 
the
 
Intervention
 
tasks.
 
â—
 
Session
 
[ADDRESS_659427]
 
been
 
randomized
 
to.
 
The
 
two
 
experimental
 
groups
 
(tobacco
 
retailer
 
and
 
nontobacco
 
retailer)
 
will
 
be
 
asked
 
to
 
enter
 
a
 
speciï¬c
 
store
 
5
 
times
 
per
 
week
 
for
 
4
 
weeks.
 
The
 
control
 
group
 
will
 
not
 
be
 
asked
 
to
 
enter
 
a
 
store.
 
 
5.3.3
 
Online
 
Session
 
3
 
Following
 
the
 
Intervention
 
Period,
 
participants
 
will
 
be
 
invited
 
to
 
complete
 
Session
 
3
 
online,
 
which
 
they
 
are
 
encouraged
 
to
 
complete
 
within
 
4
 
days
 
and
 
no
 
longer
 
than
 
1
 
week
 
(with
 
possibility
 
for
 
exceptions
 
at
 
experimenters'
 
discretion)
 
of
 
receiving
 
the
 
invitation.
 
Participants
 
will
 
complete
 
surveys;
 
an
 
image
 
rating
 
task;
 
and
 
geolocation
 
data
 
export
 
and
 
upload.
 
At
 
the
 
end
 
of
 
the
 
session,
 
participants
 
will
 
be
 
instructed
 
on
 
how
 
to
 
uninstall
 
study-related
 
smartphone
 
applications
 
and
 
turn
 
off
 
smartphone
 
location
 
tracking,
 
as
 
desired.
 
If
 
not
 
interested
 
in
 
and/or
 
potentially
 
eligible
 
for
 
the
 
scan
 
session,
 
participants
 
will
 
also
 
be
 
provided
 
with
 
a
 
debrieï¬ng
 
form,
 
which
 
includes
 
details
 
about
 
the
 
study
 
procedure
 
and
 
research
 
goals,
 
and
 
may
 
request
 
a
 
phone
 
call
 
or
 
video
 
call
 
to
 
go
 
over
 
the
 
content
 
of
 
the
 
form.
  
They
 
will
 
be
 
provided
 
with
 
a
 
Quit
 
Resources
 
document,
 
which
 
contains
 
information
 
about
 
services
 
that
 
provide
 
smoking
 
cessation
 
assistance.
 
For
 
participants
 
interested
 
in
 
being
 
screened
 
for
 
the
 
scan,
 
debriefing
 
and
 
provision
 
of
 
the
 
quit
 
resources
 
document
 
will
 
occur
 
after
 
the
 
scan
 
or
 
as
 
soon
 
as
 
scan
 
session
 
ineligibility
 
is
 
determined.
 
5.3.4
 
Optional
 
fMRI
 
session
 
â—
 
fMRI
 
Screening:
 
Participants
 
who
 
complete
 
Session
 
3
 
and
 
are
 
potentially
 
eligible
 
to
 
participate
 
in
 
the
 
optional,
 
in-person
 
fMRI
 
session
 
(as
 
determined
 
by
 
[CONTACT_6270]-report
 
questions
 
in
 
previous
 
screening
 
surveys
 
and
 
online
 
sessions)
 
may
 
be
 
informed
 
of
 
the
 
opportunity
 
and
 
invited
 
to
 
complete
 
an
 
additional,
 
optional
 
fMRI
 
screening
 
survey.
 
The
 
fMRI
 
screen
 
will
 
contain
 
questions
 
relevant
 
to
 
their
 
eligibility
 
for
 
the
 
in-person
 
component
 
of
 
the
 
study.
 
â—
 
fMRI
 
session:
 
This
 
is
 
a
 
2
 
hour
 
session.
 
After
 
confirming
 
that
 
the
 
participant
 
meets
 
any
 
COVID-19
 
screening
 
requirements
 
(e.g.,
 
symptom
 
screen,
 
temperature
 
check),
 
during
 
the
 
in-person
 
session,
 
researchers
 
will
 
review
 
the
 
consent
 
addendum
 
document
 
with
 
participants.
 
After
 
providing
 
written
 
informed
 
consent,
 
participants
 
will
 
complete
 
any
 
required
 
forms
 
(e.g.,
 
W-2,
 
additional
 
metal
 
screen)
 
and
 
provide
 
a
 
urine
 
sample
 
to
 
confirm
 
eligibility.
 
Eligible
 
participants
 
will
 
receive
 
safety
 
and
 
task-related
 
instructions/training
 
before
 
completing
 
the
 
fMRI
 
scan.
 
During
 
the
 
1-hour
 
scan
 
component
 
of
 
the
 
session,
 
participants
 
will
 
complete
 
an
 
image
 
rating
 
task.
 
Depending
 
on
 
time
 
of
 
arrival,
 
participants
 
may
 
be
 
asked
 
to
 
complete
 
a
 
brief
 
survey
 
before
 
and/or
 
after
 
the
 
scan.
 
 
 
5.[ADDRESS_659428]
 
safety
 
or
 
health.
 
Specific
 
exclusion
 
criteria
 
are
 
detailed
 
below.
 
ONLINE
 
SESSION
 
1:
 
If
 
a
 
participant's
 
cotinine
 
test
 
result
 
is
 
not
 
above
 
the
 
threshold
 
required
 
for
 
eligibility,
 
the
 
participant
 
will
 
be
 
excluded
 
from
 
continuing
 
in
 
the
 
study.
 
Participants
 
who
 
are
 
found
 
to
 
be
 
ineligible
 
during
 
Session
 
1
 
(e.g.
 
due
 
to
 
the
 
results
 
of
 
their
 
cotinine
 
tests)
 
will
 
be
 
paid
 
$[ADDRESS_659429]
 
for
 
the
 
tasks
 
they
 
completed
 
but
 
will
 
be
 
excluded
 
from
 
continuing
 
their
 
participation
 
in
 
this
 
study.
 
BASELINE
 
PERIOD:
 
If
 
participants
 
are
 
excluded
 
(e.g.,
 
for
 
responding
 
to
 
less
 
than
 
75%
 
of
 
EMA)
 
or
 
withdraw
 
during
 
the
 
baseline
 
or
 
intervention
 
periods,
 
they
 
will
 
be
 
issued
 
payment
 
on
 
their
 
Clincard
 
at
 
the
 
rate
 
of
 
$[ADDRESS_659430]
 
75%
 
of
 
EMA
 
surveys.
 
 
INTERVENTION
 
PERIOD:
 
Participants
 
in
 
the
 
experimental
 
group
 
who
 
discontinue
 
participation
 
during
 
the
 
intervention
 
period
 
will
 
also
 
be
 
paid
 
according
 
to
 
the
 
standard
 
schedule
 
for
 
EMA
 
compliance
 
($4/day
 
at
 
75%
 
or
 
higher)
 
and
 
receipt
 
submission
 
($5
 
per
 
veriï¬ed
 
daily
 
receipt).
 
Participants
 
who
 
do
 
not
 
complete
 
required
 
study
 
tasks
 
during
 
the
 
intervention
 
(e.g.,
 
submitting
 
fewer
 
than
 
20
 
store
 
receipts,
 
EMA
 
compliance
 
below
 
75%)
 
will
 
not
 
receive
 
the
 
study
 
completion
 
bonus.
 
Withdrawn
 
and
 
excluded
 
participants
 
who
 
complete
 
an
 
optional
 
offboarding
 
call
 
will
 
be
 
compensated
 
for
 
their
 
time
 
at
 
a
 
rate
 
of
 
$15/hour.
  
 
FMRI
 
SESSION:
 
Participants
 
who
 
must
 
be
 
excluded
 
or
 
asked
 
to
 
reschedule
 
by
 
[CONTACT_510086]-person
 
session
 
will
 
be
 
paid
 
$[ADDRESS_659431] awn
 
and
 
excluded
 
participants
 
are
 
sent
 
instructions
 
to
 
turn
 
off
 
location
 
tracking
 
&
 
delete
 
the
 
RealLif e
 
Exp
 
app.
 
They
 
are
 
also
 
informed
 
that
 
they
 
can
 
contact
 
[CONTACT_510087].
 
This
 
optional
 
offboar ding
 
call
 
will
 
be
 
compensated
 
for
 
their
 
time
 
at
 
a
 
rate
 
of
 
$15/hour .
 
These
 
participants
 
will
 
also
 
be
 
sent
 
a
 
link
 
to
 
submit
 
geolocation
 
data
 
for
 
a
 
ï¬nal
 
time
 
for
 
an
 
additional
 
$5
 
payment
 
(estimated
 
20
 
minutes
 
at
 
a
 
rate
 
of
 
$15/hour).
 
5.[ADDRESS_659432] awn
 
and
 
excluded
 
participants
 
are
 
sent
 
instructions
 
to
 
turn
 
off
 
location
 
tracking
 
&
 
delete
 
the
 
RealLif e
 
Exp
 
app.
 
They
 
are
 
also
 
informed
 
that
 
they
 
can
 
contact
 
[CONTACT_510087].
 
This
 
optional
 
offboar ding
 
call
 
will
 
be
 
V2025-06
 

 
compensated
 
for
 
their
 
time
 
at
 
a
 
rate
 
of
 
$15/hour .
 
These
 
participants
 
will
 
also
 
be
 
sent
 
a
 
link
 
to
 
submit
 
geolocation
 
data
 
for
 
a
 
ï¬nal
 
time
 
for
 
an
 
additional
 
$5
 
payment
 
(estimated
 
20
 
minutes
 
at
 
a
 
rate
 
of
 
$15/hour).
 
5.7
 
Safety
 
Evaluation
 
 
 
We
 
evaluated
 
safety
 
according
 
to
 
our
 
original
 
plan:
 
1.
 
 
After
 
collection
 
of
 
60
 
participants
 
(approximately
 
20
 
in
 
each
 
group)
 
and
 
120
 
participants
 
(approximately
 
40
 
in
 
each
 
group),
 
we
 
will
 
use
 
EMA
 
data
 
to
 
identify:
 
 
a.
 
The
 
distribution
 
(histogram)
 
of
 
each
 
participantâ€™s
 
daily
 
cigarette
 
consumption
 (ğ‘ ğ‘– ğ‘”/ğ‘‘ ğ‘ ğ‘¦) 
during
 
the
 
baseline
 
period
 
(
b0
)
 
i.
 
Including
 
each
 
pptâ€™s
 
mean
 
baseline
 
consumption
 
(
)&
 
standard
 
deviation
 
(
 ğ‘ ğ‘– ğ‘” ğ‘ /ğ‘‘ ğ‘ ğ‘¦
ğ‘
0ğ‘† ğ·
ğ‘
0)
b.
 
The
 
distribution
 
(histogram)
 
of
 
each
 
participantâ€™s
 
daily
 
cigarette
 
consumption
 (ğ‘ ğ‘– ğ‘”/ğ‘‘ ğ‘ ğ‘¦) 
during
 
weeks
 
3
 
and
 
4
 
of
 
the
 
intervention
 
period
 
(
i3-4)
 
i.
 
Including
 
each
 
pptâ€™s
 
mean
 
consumption
 
(
)
 
&
 
standard
 
deviation
 
for
 ğ‘ ğ‘– ğ‘” ğ‘ /ğ‘‘ ğ‘ ğ‘¦
ğ‘–
3
âˆ’
4(ğ‘† ğ·
ğ‘–
3
âˆ’
4)
intervention
 
weeks
 
3
 
and
 
4
 
 
2.
 
Participants
 
will
 
be
 
identified
 
as
 
â€œincreased
 
smokersâ€
 
if
 
their
 
average
 
daily
 
cigarette
 
consumption
 
during
 
the
 
final
 
[ADDRESS_659433]
 
deviations
 
above
 
their
 
baseline
 
mean
 
a.
 
Increased
 
smokers:
     
 
   
 
>
  
(
 
+
 
3SD)
 ğ‘ ğ‘– ğ‘” ğ‘ /ğ‘‘ ğ‘ ğ‘¦
ğ‘–
3
âˆ’
4ğ‘ ğ‘– ğ‘” ğ‘ /ğ‘‘ ğ‘ ğ‘¦
ğ‘–
3
âˆ’
4
 
3.
 
If
 
the
 
number
 
of
 
â€œincreased
 
smokersâ€
 
in
 
the
 
Tobacco
 
retailer
 
condition
 
is
 
significantly
 
(
pâ‰¤ 
.01)
 
greater
 
than
 
the
 
number
 
of
 
â€œincreased
 
smokersâ€
 
in
 
the
 
control
 
condition,
 
this
 
will
 
trigger
 
the
 
study
 
team
 
to
 
reconvene
 
for
 
a
 
reassessment
 
with
 
members
 
of
 
the
 
study
 
team,
 
the
 
Primary
 
Investigator,
 
the
 
Co-Investigators
 
who
 
have
 
expertise
 
in
 
tobacco
 
research,
 
and
 
the
 
external
 
stakeholders.
 
This
 
may
 
result
 
in
 
the
 
termination
 
of
 
this
 
arm
 
of
 
the
 
study
 
and
 
reassignment
 
of
 
future
 
participants
 
to
 
the
 
other
 
two
 
groups.
 
Additionally,
 
as
 
part
 
of
 
this
 
review,
 
we
 
will
 
reach
 
out
 
to
 
the
 
participants
 
in
 
all
 
conditions
 
who
 
met
 
the
 
criteria
 
for
 
an
 
â€œincreased
 
smokerâ€
 
to
 
offer
 
additional
 
counseling
 
on
 
smoking
 
cessation
 
resources.
  
The
 
group
 
will
 
further
 
make
 
a
 
plan
 
to
 
mitigate
 
future
 
risks
 
to
 
participants.
 
 
 
6
 
Statistical
 
Plan
 
6.1
 
Sample
 
Size
 
and
 
Power
 
Determination
 
 
Our
 
initial
 
target
 
was
 
to
 
obtain
 
60
 
complete
 
datasets
 
(meaning
 
that
 
participants
 
finished
 
Online
 
Session
 
3,
 
two
 
fMRI
 
sessions
 
[before
 
and
 
after
 
the
 
intervention
 
period],
 
and
 
also
 
completed
 
all
 
20
 
store
 
visits)
 
per
 
intervention
 
condition
 
(total
 
N
 
=
 
180).
 
Due
 
to
 
pandemic-related
 
resource
 
constraints
 
and
 
time
 
delays,
 
we
 
were
 
unable
 
to
 
reach
 
this
 
goal.
 
We
 
collected
 
the
 
maximum
 
number
 
of
 
participants
 
possible
 
with
 
the
 
resources
 
available
 
from
 
our
 
grant.
 
Prior
 
to
 
looking
 
at
 
the
 
data,
 
we
 
elected
 
to
 
randomize
 
more
 
individuals
 
into
 
the
 
experimental
 
conditions
 
than
 
to
 
the
 
control
 
condition,
 
since
 
less
 
than
 
50%
 
of
 
participants
 
typi[INVESTIGATOR_510058]
 
20
 
store
 
visits
 
and
 
provided
 
fully
 
complete
 
datasets.
 
Before
 
we
 
conducted
 
any
 
hypothesis
 
testing,
 
we
 
reassessed
 
power
 
in
 
consultation
 
with
 
our
 
study
 
teamâ€™s
 
biostatistician
 
to
 
determine
 
which
 
original
 
hypotheses
 
would
 
be
 
adequately
 
powered
 
with
 
the
 
available
 
data
 
and
 
planned
 
analysis
 
V2025-[ADDRESS_659434]
 
40
 
complete
 
datasets
 
(participants
 
who
 
completed
 
all
 
20
 
store
 
visits)
 
in
 
each
 
intervention
 
condition,
 
we
 
could
 
detect
 
interaction
 
effects
 
(time
 
*
 
group)
 
sized
 
d
 
=
 
0.1
 
with
 
95%
 
power.
 
We
 
ultimately
 
randomized
 
105
 
to
 
the
 
Non-tobacco
 
retailer
 
condition,
 
107
 
participants
 
to
 
the
 
Tobacco
 
retailer
 
condition,
 
and
 
70
 
participants
 
to
 
the
 
Control
 
condition
 
resulting
 
in
 
175
 
complete
 
datasets.
 
We
 
scanned
 
as
 
many
 
participants
 
as
 
we
 
were
 
able
 
to
 
obtain
 
within
 
constraints
 
of
 
the
 
larger
 
study.
 
Power
 
analysis
 
suggests
 
that
 
with
 
N=[ADDRESS_659435]
 
>80%
 
power
 
to
 
detect
 
effects
 
of
 
d
 
=
 
.2
 
(i.e.,
 
a
 
small
 
effect
 
size)
 
within
 
person.
 
 
6.2
 
Statistical
 
Methods
 
 
Behavioral
 
data
 
(ecological
 
momentary
 
assessment,
 
smoking
 
behavior)
 
as
 
well
 
as
 
neural
 
activity
 
aggregates
 
from
 
regions
 
of
 
interest
 
will
 
be
 
analyzed
 
using
 
the
 
statistical
 
software
 
R.
 
Data
 
will
 
be
 
analyzed
 
using
 
multi-level
 
regression
 
and
 
repeated
 
measures
 
ANOVA,
 
or
 
alternative
 
appropriate
 
statistics,
 
given
 
observed
 
distributions.
 
 
 
fMRI
 
data
 
will
 
be
 
analyzed
 
using
 
Statistical
 
Parametric
 
Mappi[INVESTIGATOR_007]
 
(SPM;
 
Wellcome
 
Trust
 
Centre
 
for
 
Neuroimaging)
 
and
 
NiPype.
 
We
 
will
 
examine
 
neural
 
responses
 
to
 
tobacco
 
marketing
 
and
 
to
 
other
 
smoking-related
 
images,
 
and
 
how
 
these
 
responses
 
relate
 
to
 
tobacco
 
marketing
 
exposure
 
in
 
the
 
real-world,
 
as
 
well
 
as
 
group
 
differences
 
in
 
these
 
responses.
 
Prior
 
to
 
analysis,
 
we
 
will
 
apply
 
standard
 
data
 
screening/cleaning
 
procedures
 
to:
 
(a)
 
screen
 
for
 
data-entry
 
errors,
 
(b)
 
check
 
for
 
outliers,
 
(c)
 
assess
 
the
 
extent
 
and
 
pattern
 
of
 
missing
 
data,
 
(d)
 
create
 
all
 
summary
 
scores
 
needed
 
for
 
analysis,
 
and
 
(e)
 
check
 
that
 
appropriate
 
assumptions
 
of
 
normality
 
are
 
met.
 
The
 
assumptions
 
underlying
 
the
 
application
 
of
 
all
 
the
 
statistical
 
methods
 
that
 
are
 
used
 
will
 
be
 
examined,
 
principally
 
through
 
the
 
use
 
of
 
standardized
 
residuals,
 
influence
 
diagnostics,
 
and
 
graphical
 
displays.
 
Neuroimaging
 
analysis
 
will
 
be
 
done
 
in
 
nipype
 
and
 
SPM12,
 
beginning
 
with
 
slice-time
 
correction,
 
realignment,
 
coregistration
 
of
 
functional
 
and
 
structural
 
images,
 
and
 
normalization
 
to
 
the
 
standard
 
Montreal
 
Neurological
 
Institute
 
(MNI)
 
brain.
 
This
 
processing
 
will
 
include
 
image
 
quality
 
assessment
 
(QA)
 
procedures
 
that
 
examine
 
global
 
and
 
ROI
 
based
 
raw
 
and
 
processed
 
temporal
 
signal-to-noise
 
ratio,
 
absolute
 
and
 
relative
 
motion,
 
and
 
visual
 
inspection.
 
Response
 
amplitude
 
(percent
 
signal
 
change)
 
within
 
each
 
ROI
 
will
 
be
 
extracted
 
using
 
SPM
 
or
 
nipype
 
tools;
 
primary
 
tests
 
of
 
our
 
aims
 
will
 
be
 
performed
 
in
 
R,
 
Î±=.05,
 
two
 
tailed.
 
Whole-brain
 
exploratory
 
analyses
 
will
 
be
 
performed
 
in
 
SPM12,
 
thresholded
 
to
 
correspond
 
to
 
p<.05,
 
FDR-corrected.
 
6.3
 
Control
 
of
 
Bias
 
and
 
Confounding
 
 
 
Participants
 
who
 
complete
 
the
 
required
 
tasks
 
during
 
the
 
baseline
 
period
 
(Period
 
1)
 
will
 
be
 
randomized.
 
All
 
participants
 
must
 
be
 
able
 
to
 
complete
 
tasks
 
in
 
any
 
condition
 
to
 
participate,
 
and
 
so
 
all
 
participants
 
have
 
an
 
equal
 
chance
 
to
 
be
 
in
 
any
 
of
 
the
 
conditions.
 
Conditions
 
are
 
coded
 
with
 
a
 
numeric
 
value
 
so
 
they
 
can
 
be
 
analyzed
 
by
 
[CONTACT_510088]â€™
 
specific
 
group
 
assignment.
 
 
6.3.[ADDRESS_659436]
 
descriptive
 
statistics
 
(including
 
mean
 
and
 
standard
 
deviation
 
for
 
continuous
 
variables
 
such
 
as
 
age
 
and
 
standard
 
percentages
 
for
 
categorical
 
variables
 
such
 
as
 
gender).
 
 
V2025-[ADDRESS_659437]
 
 
 
Daily
 
cigarette
 
and
 
craving
 
analyses
 
 
Hypothesis
 
1:
 
Reported
 
craving
 
will
 
be
 
higher
 
for
 
those
 
in
 
the
 
Tobacco
 
retailer
 
condition,
 
relative
 
to
 
the
 
Control
 
and
 
Nontobacco
 
retailer
 
conditions,
 
during
 
the
 
intervention
 
phase,
 
but
 
not
 
the
 
baseline
 
phase.
 
To
 
test
 
hypothesis
 
1,
 
we
 
will
 
use
 
a
 
linear
 
mixed
 
effects
 
model
 
(in
 
R).
 
To
 
examine
 
associations
 
between
 
study
 
phase
 
and
 
craving,
 
we
 
will
 
create
 
a
 
binary
 
Study
 
Phase
 
variable
 
indicating
 
whether
 
an
 
observation
 
for
 
a
 
participant
 
occurred
 
during
 
the
 
baseline
 
(0)
 
versus
 
intervention
 
(1)
 
phase.
 
To
 
examine
 
associations
 
between
 
condition
 
assignment
 
and
 
craving,
 
we
 
will
 
create
 
two
 
dummy
 
coded
 
variables
 
indicating
 
the
 
condition
 
assignment
 
for
 
each
 
participant.
 
A
 
Control
 
condition
 
variable
 
indicates
 
whether
 
the
 
condition
 
assignment
 
is
 
the
 
Control
 
condition
 
(1)
 
or
 
the
 
other
 
two
 
conditions
 
(i.e.,
 
Tobacco
 
and
 
nontobacco
 
retailer)
 
(0).
 
A
 
Nontobacco
 
retailer
 
condition
 
variable
 
indicates
 
whether
 
the
 
condition
 
is
 
the
 
Nontobacco
 
retailer
 
condition
 
(1)
 
or
 
the
 
other
 
two
 
conditions
 
(i.e.,
 
Control
 
and
 
Tobacco
 
retailer
 
conditions)
 
(0).
 
Thus,
 
the
 
Tobacco
 
retailer
 
condition
 
is
 
indicated
 
when
 
both
 
the
 
Control
 
condition
 
and
 
Nontobacco
 
retailer
 
condition
 
variables
 
are
 
equal
 
to
 
0.
 
We
 
will
 
test
 
the
 
interactions
 
between
 
study
 
phase
 
and
 
condition
 
assignment.
 
 
At
 
level
 
1,
 
the
 
formal
 
model
 
is
 
constructed
 
as:
 
 
Craving
it
 
=
  
Î²
0
i
 
+
 
Î²
1
i
StudyPhase
it
 
+
 
e
it
 
 
 
 
where
 
Î²
0
 
is
 
the
 
intercept,
 
indicating
 
the
 
average
 
level
 
of
 
craving
 
for
 
the
 
prototypi[INVESTIGATOR_510059];
 
Î²
1
i
  
indicates
 
the
 
difference
 
in
 
the
 
level
 
of
 
craving
 
between
 
the
 
baseline
 
phase
 
and
 
intervention
 
phase;
 
and
 
e
it
 
are
 
residuals
 
that
 
are
 
allowed
 
to
 
autocorrelate.
 
 
Person-specific
 
intercepts
 
and
 
associations
 
(from
 
the
 
Level
 
1
 
model)
 
are
 
specified
 
(at
 
Level
 
2)
 
as:
 
 
 
Î²
0
i
 
=
 
Î³
00
 
+
 
Î³
01
ControlCondition
i
+Î³
02
NontobaccoRetailerCondition
i
 
+
 
u
0
i
 
 
Î²
1
i
 
=
 
Î³
10
 
+Î³
11
ControlCondition
i
+Î³
21
NontobaccoRetailerCondition
i
 
+
 
u
[ADDRESS_659438]
 
the
 
key
 
hypotheses
 
that
 
craving
 
will
 
be
 
higher
 
for
 
those
 
in
 
the
 
Tobacco
 
retailer
 
condition,
 
relative
 
to
 
the
 
Control
 
condition,
 
during
 
the
 
intervention
 
phase
 
but
 
not
 
the
 
baseline
 
phase
 
(Î³
11
)
 
and
 
that
 
craving
 
will
 
be
 
higher
 
for
 
those
 
in
 
the
 
Tobacco
 
retailer
 
condition,
 
relative
 
to
 
the
 
Nontobacco
 
retailer
 
condition,
 
during
 
the
 
intervention
 
phase
 
but
 
not
 
the
 
baseline
 
phase
 
(Î³
21
).
 
 
 
Hypothesis
 
2:
 
Reported
 
cigarettes
 
smoked
 
will
 
be
 
higher
 
for
 
those
 
in
 
the
 
Tobacco
 
retailer
 
condition,
 
relative
 
to
 
the
 
Control
 
and
 
Nontobacco
 
retailer
 
conditions,
 
during
 
the
 
intervention
 
phase,
 
but
 
not
 
the
 
baseline
 
phase.
 
To
 
test
 
hypothesis
 
2,
 
we
 
will
 
use
 
a
 
linear
 
mixed
 
effects
 
model
 
(in
 
R).
 
To
 
examine
 
associations
 
between
 
study
 
phase
 
and
 
cigarettes
 
smoked,
 
we
 
will
 
create
 
a
 
binary
 
Study
 
Phase
 
variable
 
indicating
 
whether
 
an
 
observation
 
for
 
a
 
participant
 
occurred
 
during
 
the
 
baseline
 
(0)
 
versus
 
intervention
 
(1)
 
phase.
 
To
 
examine
 
associations
 
between
 
condition
 
assignment
 
and
 
cigarettes
 
smoked,
 
we
 
will
 
create
 
two
 
dummy
 
coded
 
variables
 
indicating
 
the
 
condition
 
assignment
 
for
 
each
 
participant.
 
A
 
Control
 
condition
 
variable
 
indicates
 
whether
 
the
 
V2025-06
 

 
condition
 
assignment
 
is
 
the
 
Control
 
condition
 
(1)
 
or
 
the
 
other
 
two
 
conditions
 
(i.e.,
 
Nontobacco
 
retailer
 
and
 
Tobacco
 
retailer
 
conditions)
 
(0).
 
A
 
Nontobacco
 
retailer
 
condition
 
variable
 
indicates
 
whether
 
the
 
condition
 
is
 
the
 
Nontobacco
 
retailer
 
condition
 
(1)
 
or
 
the
 
other
 
two
 
conditions
 
(i.e.,
 
Control
 
and
 
Tobacco
 
retailer
 
conditions)
 
(0).
 
Thus,
 
the
 
Tobacco
 
retailer
 
condition
 
is
 
indicated
 
when
 
both
 
the
 
Control
 
condition
 
and
 
Nontobacco
 
retailer
 
condition
 
variables
 
are
 
equal
 
to
 
0.
 
We
 
will
 
test
 
the
 
interactions
 
between
 
the
 
study
 
phase
 
and
 
condition
 
assignment.
 
 
At
 
level
 
1,
 
the
 
formal
 
model
 
is
 
constructed
 
as:
 
 
Smoking
it
 
=
  
Î²
0
i
 
+
 
Î²
1
i
StudyPhase
it
 
+
 
e
it
 
 
 
 
where
 
Î²
0
 
is
 
the
 
intercept,
 
indicating
 
the
 
average
 
number
 
of
 
cigarettes
 
smoked
 
per
 
day
 
for
 
the
 
prototypi[INVESTIGATOR_510059];
 
Î²
1
i
  
indicates
 
the
 
difference
 
in
 
the
 
level
 
of
 
craving
 
between
 
the
 
baseline
 
phase
 
and
 
intervention
 
phase;
 
and
 
e
it
 
are
 
residuals
 
that
 
are
 
allowed
 
to
 
autocorrelate.
 
 
Person-specific
 
intercepts
 
and
 
associations
 
(from
 
the
 
Level
 
1
 
model)
 
are
 
specified
 
(at
 
Level
 
2)
 
as:
 
 
 
Î²
0
i
 
=
 
Î³
00
 
+
 
Î³
01
ControlCondition
i
+Î³
02
NontobaccoRetailerCondition
i
 
+
 
u
0
i
 
 
Î²
1
i
 
=
 
Î³
10
 
+Î³
11
ControlCondition
i
+Î³
21
NontobaccoRetailerCondition
i
 
+
 
u
[ADDRESS_659439]
 
the
 
key
 
hypotheses
 
that
 
the
 
number
 
of
 
cigarettes
 
smoked
 
will
 
be
 
higher
 
for
 
those
 
in
 
the
 
Tobacco
 
retailer
 
condition,
 
relative
 
to
 
the
 
Control
 
condition,
 
during
 
the
 
intervention
 
phase
 
but
 
not
 
the
 
baseline
 
phase
 
(Î³
11
)
 
and
 
that
 
the
 
number
 
of
 
cigarettes
 
smoked
 
will
 
be
 
higher
 
for
 
those
 
in
 
the
 
Tobacco
 
retailer
 
condition,
 
relative
 
to
 
the
 
Nontobacco
 
retailer
 
condition,
 
during
 
the
 
intervention
 
phase
 
but
 
not
 
the
 
baseline
 
phase
 
(Î³
21
).
 
 
for
 
fMRI-related
 
analyses:
 
 
Hypothesis
 
1:
 
To
 
test
 
hypothesis
 
1
 
-
 
that
 
neural
 
activity
 
in
 
smoking
 
cue
 
reactivity
 
regions
 
will
 
be
 
greater
 
in
 
response
 
to
 
standardized
 
images
 
of
 
cigarette
 
cues
 
(standard
 
smoking
 
cues)
 
than
 
in
 
response
 
to
 
standardized,
 
approximately
 
compositionally
 
matched
 
sets
 
of
 
images
 
of
 
non-cigarette
 
cues
 
(standard
 
nonsmoking
 
cues)
 
-
 
we
 
will
 
average
 
neural
 
activation
 
across
 
voxels
 
in
 
the
 
aggregate
 
craving
 
ROI
 
to
 
assess
 
differences
 
in
 
neural
 
cue
 
reactivity
 
between
 
standardized
 
smoking
 
cue
 
blocks
 
and
 
standardized
 
non-smoking
 
cue
 
blocks.
 
Specifically,
 
we
 
will
 
extract
 
contrast
 
estimates
 
of
 
each
 
condition
 
compared
 
to
 
rest,
 
from
 
the
 
aggregate
 
craving
 
ROI.
 
We
 
will
 
then
 
use
 
a
 
linear
 
mixed
 
effects
 
model
 
(in
 
R),
 
to
 
account
 
for
 
some
 
participants
 
having
 
two
 
sets
 
of
 
fMRI
 
scans.
 
To
 
examine
 
associations
 
between
 
neural
 
activity
 
in
 
the
 
cue
 
reactivity
 
ROI
 
and
 
the
 
two
 
task
 
conditions
 
(standard
 
smoking
 
and
 
nonsmoking
 
cues),
 
we
 
will
 
create
 
a
 
binary
 
TaskCondition
 
variable
 
indicating
 
whether
 
an
 
observation
 
occurred
 
during
 
the
 
standard
 
smoking
 
cue
 
blocks
 
(1)
 
vs
 
standard
 
non-smoking
 
cue
 
blocks
 
(0).
 
If
 
we
 
do
 
not
 
find
 
a
 
significant
 
difference
 
between
 
these
 
conditions
 
in
 
the
 
ROIs
 
defined
 
in
 
the
 
pi[INVESTIGATOR_510060],
 
we
 
will
 
examine
 
whole-brain
 
effects
 
using
 
MarsBaR
 
and
 
will
 
define
 
cue
 
reactivity
 
ROIs
 
for
 
hypotheses
 
5
 
and
 
6
 
based
 
on
 
prior
 
meta-analyses
 
(e.g.,
 
Engelmann
 
et
 
al.,
 
2012;
 
Lin
 
et
 
al.,
 
2020)
.
 
 
Lme
 
(ROI
 
~
 
TaskCondition,
 
random
 
=
 
~
 
1
 
|
 
Participant
 
/
 
Session)
 
)
 
 
Where
 
TaskCondition
 
represents
 
standard
 
smoking
 
cues
 
vs
 
standard
 
nonsmoking
 
cues.
 
V2025-06
 

 
 
Hypothesis
 
2
:
 
To
 
test
 
hypothesis
 
2
 
-
 
that
 
neural
 
activity
 
in
 
smoking
 
cue
 
reactivity
 
regions
 
will
 
be
 
greater
 
in
 
response
 
to
 
viewing
 
photos
 
of
 
the
 
cash
 
register
 
area
 
at
 
a
 
convenience
 
store
 
with
 
tobacco
 
marketing
 
and
 
products
 
(tobacco
 
retail
 
images),
 
than
 
to
 
photos
 
of
 
the
 
cash
 
register
 
area
 
at
 
a
 
pharmacy
 
store
 
without
 
tobacco
 
marketing
 
and
 
products
 
(nontobacco
 
retail
 
images)
 
-
 
-
  
we
 
will
 
use
 
a
 
parallel
 
model
 
to
 
the
 
model
 
specified
 
for
 
Hypothesis
 
1,
 
where
 
for
 
Hypothesis
 
2,
 
the
 
TaskCondition
 
variable
 
represents
 
tobacco
 
retail
 
images
 
vs
 
nontobacco
 
retail
 
images.
 
6.3.3
 
Interim
 
Analysis
 
 
At
 
two
 
time
 
points
 
during
 
data
 
collection,
 
we
 
will
 
assess
 
whether
 
the
 
study
 
is
 
producing
 
unexpectedly
 
positive
 
or
 
negative
 
effects
 
on
 
participant
 
outcomes.
 
After
 
collection
 
of
 
60
 
participants
 
(approximately
 
20
 
in
 
each
 
group)
 
and
 
120
 
participants
 
(approximately
 
40
 
in
 
each
 
group),
 
we
 
will
 
test
 
whether
 
individuals
 
in
 
the
 
Tobacco
 
retailer
 
condition
 
have
 
significantly
 
changed
 
the
 
number
 
of
 
cigarettes
 
that
 
they
 
smoke
 
per
 
day
 
(as
 
described
 
in
 
5.7).
 
If
 
this
 
group
 
of
 
participants
 
changes
 
their
 
cigarette
 
consumption
 
by
 
a
 
clinically
 
significant
 
level,
 
we
 
will
 
stop
 
assigning
 
participants
 
to
 
that
 
group
 
and
 
assign
 
all
 
further
 
participants
 
equally
 
to
 
the
 
other
 
groups.
 
 
7
 
Safety
 
and
 
Adverse
 
Events
 
7.1
 
Definitions
 
7.1.1
 
Adverse
 
Event
 
An
 
adverse
 
event
 
(AE)
 
is
 
any
 
symptom,
 
sign,
 
illness
 
or
 
experience
 
that
 
develops
 
or
 
worsens
 
in
 
severity
 
during
 
the
 
course
 
of
 
the
 
study.
  
Intercurrent
 
illnesses
 
or
 
injuries
 
should
 
be
 
regarded
 
as
 
adverse
 
events.
  
 
 
Incidental
 
findings
 
in
 
the
 
fMRI
 
component
 
of
 
this
 
study
  
are
 
considered
 
to
 
be
 
adverse
 
events
 
if
 
the
 
finding:
 
â—
 
results
 
in
 
study
 
withdrawal
 
â—
 
is
 
associated
 
with
 
a
 
serious
 
adverse
 
event
 
â—
 
is
 
associated
 
with
 
clinical
 
signs
 
or
 
symptoms
 
â—
 
leads
 
to
 
additional
 
treatment
 
or
 
to
 
further
 
diagnostic
 
tests
 
â—
 
is
 
considered
 
by
 
[CONTACT_510089]
 
7.1.2
 
Serious
 
Adverse
 
Event
 
 
Serious
 
Adverse
 
Event
 
Adverse
 
events
 
are
 
classified
 
as
 
serious
 
or
 
non-serious.
  
A
 
serious
 
adverse
 
event
 
is
 
any
 
AE
 
that
 
is:
 
 
â—
 
fatal
 
â—
 
life-threatening
 
â—
 
requires
 
or
 
prolongs
 
hospi[INVESTIGATOR_510061]
 
â—
 
results
 
in
 
persistent
 
or
 
significant
 
disability
 
or
 
incapacity
 
â—
 
required
 
intervention
 
to
 
prevent
 
permanent
 
impairment
 
or
 
damage
 
â—
 
a
 
congenital
 
anomaly
 
or
 
birth
 
defect
 
â—
 
an
 
important
 
medical
 
event
 
 
 
V2025-[ADDRESS_659440]
 
medical
 
or
 
other
 
life
 
events
 
that
 
may
 
be
 
considered
 
adverse
 
events
 
as
 
reported
 
by
 
[CONTACT_4317]
 
(e.g.,
 
hospi[INVESTIGATOR_510062]).
 
Information
 
on
 
all
 
adverse
 
events
 
will
 
be
 
recorded
 
in
 
the
 
source
 
document
 
immediately
 
upon
 
discovery,
 
and
 
also
 
in
 
the
 
appropriate
 
adverse
 
event
 
module
 
of
 
the
 
case
 
report
 
form
 
(CRF).
  
All
 
clearly
 
related
 
signs,
 
symptoms,
 
and
 
abnormal
 
incidental
 
findings
 
results
 
will
 
be
 
recorded
 
in
 
the
 
source
 
document.
 
 
All
 
adverse
 
events
 
occurring
 
during
 
the
 
study
 
period
 
will
 
be
 
recorded.
  
The
 
clinical
 
course
 
of
 
each
 
event
 
will
 
be
 
followed
 
until
 
resolution,
 
stabilization,
 
or
 
until
 
it
 
has
 
been
 
determined
 
that
 
the
 
study
 
intervention
 
or
 
participation
 
is
 
not
 
the
 
cause.
  
Serious
 
and
 
related
 
adverse
 
events
 
that
 
are
 
still
 
ongoing
 
at
 
the
 
end
 
of
 
the
 
study
 
period
 
will
 
be
 
followed
 
up
 
to
 
determine
 
the
 
final
 
outcome.
  
Any
 
serious
 
adverse
 
event
 
that
 
occurs
 
during
 
an
 
in-person
 
session
 
and
 
is
 
considered
 
to
 
be
 
possibly
 
related
 
to
 
the
 
study
 
intervention
 
or
 
study
 
participation
 
will
 
be
 
recorded
 
and
 
reported.
 
 
7.3
 
Relationship
 
of
 
AE
 
to
 
Study
 
 
â€¢
  
 
Definitely
 
Related
 
â€“
 
There
 
is
 
clear
 
evidence
 
to
 
suggest
 
a
 
causal
 
relationship,
 
and
 
other
 
possible
 
contributing
 
factors
 
can
 
be
 
ruled
 
out.
 
The
 
clinical
 
event,
 
including
 
an
 
abnormal
 
laboratory
 
test
 
result,
 
occurs
 
in
 
a
 
plausible
 
time
 
relationship
 
to
 
study
 
procedures
 
administration
 
and
 
cannot
 
be
 
explained
 
by
 
[CONTACT_264952].
 
The
 
response
 
to
 
withdrawal
 
of
 
the
 
study
 
procedures
 
should
 
be
 
clinically
 
plausible.
 
The
 
event
 
must
 
be
 
pharmacologically
 
or
 
phenomenologically
 
definitive.
 
â€¢
  
 
Probably
 
Related
 
â€“
 
There
 
is
 
evidence
 
to
 
suggest
 
a
 
causal
 
relationship,
 
and
 
the
 
influence
 
of
 
other
 
factors
 
is
 
unlikely.
 
The
 
clinical
 
event,
 
including
 
an
 
abnormal
 
laboratory
 
test
 
result,
 
occurs
 
within
 
a
 
reasonable
 
time
 
after
 
administration
 
of
 
the
 
study
 
procedures,
 
is
 
unlikely
 
to
 
be
 
attributed
 
to
 
concurrent
 
disease
 
or
 
other
 
drugs
 
or
 
chemicals,
 
and
 
follows
 
a
 
clinically
 
reasonable
 
response
 
on
 
withdrawal.
 
â€¢
  
 
Potentially
 
Related
 
â€“
 
There
 
is
 
some
 
evidence
 
to
 
suggest
 
a
 
causal
 
relationship
 
(e.g.,
 
the
 
event
 
occurred
 
within
 
a
 
reasonable
 
time
 
after
 
administration
 
of
 
study
 
procedures).
 
However,
 
other
 
factors
 
may
 
have
 
contributed
 
to
 
the
 
event
 
(e.g.,
 
the
 
participantâ€™s
 
clinical
 
condition,
 
other
 
concomitant
 
events).
 
Although
 
an
 
AE
 
may
 
rate
 
only
 
as
 
â€œpossibly
 
relatedâ€
 
soon
 
after
 
discovery,
 
it
 
can
 
be
 
flagged
 
as
 
requiring
 
more
 
information
 
and
 
later
 
be
 
upgraded
 
to
 
â€œprobably
 
relatedâ€
 
or
 
â€œdefinitely
 
relatedâ€,
 
as
 
appropriate.
 
â€¢
  
 
Unlikely
 
to
 
be
 
related
 
â€“
 
A
 
clinical
 
event,
 
including
 
an
 
abnormal
 
laboratory
 
test
 
result,
 
whose
 
temporal
 
relationship
 
to
 
study
 
procedures
 
administration
 
makes
 
a
 
causal
 
relationship
 
improbable
 
(e.g.,
 
the
 
event
 
did
 
not
 
occur
 
within
 
a
 
reasonable
 
time
 
after
 
administration
 
of
 
the
 
study
 
procedures)
 
and
 
in
 
which
 
other
 
drugs
 
or
 
chemicals
 
or
 
underlying
 
disease
 
provides
 
plausible
 
explanations
 
(e.g.,
 
the
 
participantâ€™s
 
clinical
 
condition,
 
other
 
concomitant
 
treatments).
 
â€¢
  
 
Not
 
Related
 
â€“
 
The
 
AE
 
is
 
completely
 
independent
 
of
 
study
 
procedures
 
administration,
 
and/or
 
evidence
 
exists
 
that
 
the
 
event
 
is
 
definitely
 
related
 
to
 
another
 
etiology.
 
 
 
The
 
PI
 
[INVESTIGATOR_510063].
 
 
7.4
 
Reporting
 
of
 
Adverse
 
Events
 
and
 
Unanticipated
 
Problems
 
 
V2025-06
 

 
The
 
Investigator
 
will
 
promptly
 
notify
 
the
 
Penn
 
IRB
 
of
 
all
 
on-site
 
unanticipated,
 
Serious
 
Adverse
 
Events
 
that
 
are
 
related
 
to
 
the
 
research
 
activity.
 
Other
 
unanticipated
 
problems
 
related
 
to
 
the
 
research
 
involving
 
risk
 
to
 
subjects
 
or
 
others
 
will
 
also
 
be
 
reported
 
promptly.
 
Written
 
reports
 
will
 
be
 
filed
 
using
 
the
 
HS-ERA
 
and
 
in
 
accordance
 
with
 
the
 
Penn
 
IRB
 
timeline
 
of
 
10
 
working
 
days.
  
All
 
instances
 
of
 
related
 
SAEs
 
will
 
be
 
reported
 
to
 
the
 
appropriate
 
IRB
 
and
 
the
 
NCI
 
Program
 
Officer
 
within
 
24-hours
 
of
 
discovery,
 
whereas
 
probably
 
or
 
definitely
 
related
 
SAEs
 
will
 
be
 
reported
 
to
 
the
 
appropriate
 
IRBs
 
within
 
10
 
days
 
of
 
occurrence
 
using
 
the
 
on-line
 
system.
 
 
7.4.1
 
Follow-up
 
Report
 
If
 
an
 
AE
 
has
 
not
 
resolved
 
at
 
the
 
time
 
of
 
the
 
initial
 
report
 
and
 
new
 
information
 
arises
 
that
 
changes
 
the
 
investigatorâ€™s
 
assessment
 
of
 
the
 
event,
 
a
 
follow-up
 
report
 
including
 
all
 
relevant
 
new
 
or
 
reassessed
 
information
 
(e.g.,
 
concomitant
 
medication,
 
medical
 
history)
 
should
 
be
 
submitted
 
to
 
the
 
IRB.
 
The
 
investigator
 
is
 
responsible
 
for
 
ensuring
 
that
 
all
 
SAEs
 
that
 
are
 
probably
 
or
 
definitely
 
related
 
to
 
the
 
study
 
are
 
followed
 
until
 
either
 
resolved
 
or
 
stable.
 
 
7.4.2
 
Investigator
 
reporting:
 
notifying
 
the
 
study
 
sponsor
 
 
The
 
procedures
 
for
 
adverse
 
event
 
reporting
 
are
 
consistent
 
with
 
NIH
 
and
 
UPenn-specific
 
guidelines
 
and
 
are
 
as
 
follows:
 
1)
 
Report
 
all
 
instances
 
of
 
related
 
SAEs
 
to
 
the
 
NCI
 
Program
 
Officer
 
(in
 
addition
 
to
 
the
 
IRB,
 
as
 
mentioned
 
above)
 
within
 
24-hours
 
of
 
occurrence
 
or
 
discovery.2)
 
Inform
 
all
 
members
 
of
 
the
 
study
 
team
 
actively
 
involved
 
in
 
data
 
collection
 
about
 
any
 
and
 
all
 
reports
 
of
 
adverse
 
events;
 
and
 
2)
 
Notify
 
the
 
NCI
 
Program
 
Officer
 
of
 
any
 
suspension/termination
 
of
 
IRB
 
approval
 
and
 
any
 
actions
 
taken
 
by
 
[CONTACT_510090]
 
[ADDRESS_659441]
 
staff
 
and
 
IRB
 
at
 
the
 
University
 
of
 
Pennsylvania.
 
The
 
IRB
 
reviewed
 
the
 
study,
 
including
 
any
 
adverse
 
events
 
(AEs)
 
and
 
serious
 
adverse
 
events
 
(SAEs).
 
The
 
Principal
 
Investigator,
 
[CONTACT_510117],
 
Ph.D.,
 
was
 
responsible
 
for
 
overseeing
 
and
 
completing
 
the
 
monitoring
 
process
 
in
 
collaboration
 
with
 
the
 
Research
 
Director,
 
[CONTACT_510118],
 
Ph.D.
  
Any
 
deviations
 
and
 
potentially
 
serious
 
and
 
related
 
adverse
 
events
 
were
 
reviewed
 
by
 
[INVESTIGATOR_124].
 
Falk
 
and
 
[CONTACT_510119].
 
The
 
research
 
staff
 
members
 
were
 
responsible
 
for
 
collecting
 
and
 
recording
 
all
 
data,
 
as
 
well
 
as
 
maintaining
 
subject
 
privacy
 
and
 
data
 
privacy.
 
Any
 
inconsistencies/deviations
 
were
 
documented.
 
 
 
Our
 
original
 
target
 
was
 
that
 
enrollment
 
would
 
be
 
complete
 
when
 
180
 
subjects
 
were
 
consented
 
and
 
completed
 
the
 
study
 
with
 
usable
 
data
 
(see
 
section
 
6.1
 
for
 
an
 
updated
 
explanation
 
of
 
practical
 
constraints
 
that
 
arose
 
during
 
final
 
data
 
collection).
 
Individuals
 
were
 
screened
 
prior
 
to
 
admission
 
into
 
the
 
study
 
and
 
those
 
at
 
risk
 
for
 
adverse
 
reactions
 
were
 
excluded.
 
Participants
 
enrolled
 
were
 
monitored
 
closely
 
for
 
AEs.
 
 
  
 
The
 
following
 
monitoring
 
activities
 
were
 
conducted
 
by
 
[INVESTIGATOR_124].
 
Falk
 
and
 
study
 
staff
 
according
 
to
 
standard
 
operating
 
procedures.
 
 
 
V2025-06
 

 
Protocol
 
Monitoring
:
 
Protocol
 
monitoring
 
includes
 
a
 
survey
 
of
 
those
 
activities
 
that
 
are
 
associated
 
with
 
protocol
 
adherence
 
such
 
as
 
study
 
visit
 
deviation,
 
and
 
violation
 
of
 
inclusion/exclusion
 
criteria.
 
All
 
accrued
 
cases
 
will
 
be
 
subjected
 
to
 
protocol
 
monitoring
 
throughout
 
the
 
duration
 
of
 
the
 
study.
 
 
 
 
Data
 
Auditing
:
 
[CONTACT_510120]
 
will
 
review
 
safety
 
and
 
efficacy.
 
All
 
accrued
 
cases
 
will
 
be
 
subjected
 
to
 
auditing
 
throughout
 
the
 
duration
 
of
 
the
 
study.
 
A
 
Study
 
Binder
 
Review
 
will
 
include
 
the
 
following
 
essential
 
documents:
 
IRB
 
Protocol,
 
Consent
 
Form
 
and
 
Amendment
 
Approvals,
 
IRB
 
Closure
 
Letter,
 
Human
 
Subjects
 
Certifications,
 
Protocol
 
and
 
Amendment
 
Signature
 
[CONTACT_68615],
 
Curriculum
 
Vitae,
 
Financial
 
Disclosure
 
Questionnaires,
 
and
 
Monitoring
 
Log.
 
Additional
 
monitoring
 
may
 
include:
 
source
 
documentation
 
verification;
 
adverse
 
event
 
documentation;
 
and
 
facility
 
assessment.
 
During
 
the
 
course
 
of
 
the
 
study,
 
safety
 
and
 
data
 
quality
 
monitoring
 
will
 
be
 
performed
 
on
 
an
 
ongoing
 
basis
 
by
 
[CONTACT_510091],
 
Research
 
Director,
 
and
 
Principal
 
Investigator.
  
The
 
Research
 
Coordinators
 
will
 
be
 
responsible
 
for
 
collecting
 
and
 
recording
 
all
 
data.
 
â–ª
 
Assessing
 
Adverse
 
Events:
 
Monitoring
 
for
 
adverse
 
events
 
will
 
be
 
conducted
 
in
 
real
 
time
 
by
 
[CONTACT_510092].
 
Falk
 
and
 
[CONTACT_510119].
 
Based
 
on
 
previous
 
experience,
 
we
 
do
 
not
 
expect
 
there
 
to
 
be
 
SAEs
 
or
 
persistent
 
adverse
 
events.
 
However,
 
it
 
is
 
possible
 
that
 
injuries
 
will
 
occur
 
as
 
a
 
result
 
of
 
fMRI
 
scanning,
 
for
 
example
 
if
 
participants
 
do
 
not
 
fully
 
disclose
 
the
 
presence
 
of
 
metal
 
implants
 
in
 
their
 
body.
 
It
 
is
 
possible
 
that
 
our
 
experimental
 
manipulation
 
will
 
have
 
unexpectedly
 
large
 
effects
 
on
 
participant
 
outcomes.
 
As
 
described
 
above,
 
we
 
will
 
institute
 
a
 
stoppi[INVESTIGATOR_510064].
 
The
 
PI
 
[INVESTIGATOR_510065]
 
a
 
serious
 
and
 
related
 
adverse
 
event
 
and
 
will
 
refer
 
subjects
 
to
 
a
 
physician
 
(i.e.,
 
specialist)
 
as
 
clinically
 
indicated.
 
All
 
AEs
 
and
 
SAEs
 
will
 
be
 
documented
 
on
 
an
 
Adverse
 
Event
 
Report
 
Form.
 
This
 
information
 
will,
 
in
 
turn,
 
be
 
reported
 
immediately
 
to
 
all
 
necessary
 
regulatory
 
committees.
 
o
 
Adverse
 
Event
 
Reporting:
 
Any
 
serious
 
and
 
related
 
adverse
 
event
 
case
 
will
 
be
 
reviewed
 
by
 
[INVESTIGATOR_124].
 
Falk.
  
After
 
removal
 
of
 
identification
 
information,
 
all
 
serious
 
adverse
 
events
 
will
 
be
 
reported
 
to
 
the
 
University
 
of
 
Pennsylvania
 
Institutional
 
Review
 
Board,
 
the
 
CTSRMC,
 
and
 
the
 
funding
 
agency.
  
All
 
adverse
 
events
 
will
 
be
 
recorded.
 
 
 
Incidental
 
Findings:
 
The
 
fMRI
 
scans
 
conducted
 
in
 
this
 
study
 
are
 
not
 
indicated
 
to
 
be
 
clinically
 
diagnostic.
 
However,
 
if
 
any
 
incidental
 
findings
 
are
 
noted
 
by
 
[CONTACT_510093],
 
the
 
subject
 
will
 
be
 
advised
 
to
 
consult
 
a
 
neurologist.
 
 
 
Data
 
Security
:
 
Using
 
network
 
firewall
 
technologies,
 
the
 
database
 
is
 
designed
 
to
 
prevent
 
the
 
three
 
major
 
sources
 
of
 
data
 
security
 
problems:
 
unauthorized
 
internal
 
access
 
to
 
data,
 
external
 
access
 
to
 
data,
 
and
 
malicious
 
intent
 
to
 
destroy
 
data
 
and
 
systems.
 
Controlled
 
user
 
access
 
will
 
help
 
ensure
 
that
 
only
 
appropriate
 
and
 
authorized
 
personnel
 
are
 
able
 
to
 
view,
 
access,
 
and
 
modify
 
study
 
data.
 
 
 
Staff
 
Training:
 
Staff
 
training
 
will
 
consist
 
of
 
an
 
explanation
 
and
 
review
 
of
 
the
 
protocol,
 
and
 
a
 
training
 
period,
 
during
 
which
 
all
 
sessions
 
conducted
 
by
 
[CONTACT_510094]
 
a
 
senior
 
staff
 
member.
 
The
 
duties
 
of
 
each
 
staff
 
person
 
will
 
be
 
outlined
 
and
 
all
 
applicable
 
regulations
 
will
 
be
 
reviewed.
 
A
 
manual
 
of
 
Standard
 
Operating
 
Procedures
 
will
 
be
 
used
 
for
 
staff
 
training.
 
Senior
 
personnel
 
will
 
supervise
 
junior
 
staff
 
and
 
provide
 
re-training
 
in
 
the
 
study
 
protocol
 
as
 
needed.
 
V2025-06
 

 
â–ª
 
Evidence
 
of
 
Training
 
in
 
Human
 
Subject
 
Research:
 
All
 
research
 
personnel
 
associated
 
with
 
this
 
study
 
have
 
completed
 
(or
 
successfully
 
transferred
 
credit
 
for)
 
the
 
University
 
of
 
Pennsylvaniaâ€™s
 
Collaborative
 
Institutional
 
Training
 
Initiative
 
(CITI
 
program),
 
or
 
their
 
respective
 
university
 
equivalent,
 
or
 
the
 
NIH
 
patient
 
oriented
 
research
 
training
 
program,
 
as
 
well
 
as
 
HIPAA
 
Compliance
 
Training.
 
 
 
 
[ADDRESS_659442]
 
of
 
1996
 
(HIPAA).
  
Those
 
regulations
 
require
 
a
 
signed
 
subject
 
authorization
 
informing
 
the
 
subject
 
of
 
the
 
following:
 
 
â—
 
What
 
protected
 
health
 
information
 
(PHI)
 
will
 
be
 
collected
 
from
 
subjects
 
in
 
this
 
study
 
â—
 
Who
 
will
 
have
 
access
 
to
 
that
 
information
 
and
 
why
 
â—
 
Who
 
will
 
use
 
or
 
disclose
 
that
 
information
 
â—
 
The
 
rights
 
of
 
a
 
research
 
subject
 
to
 
revoke
 
their
 
authorization
 
for
 
use
 
of
 
their
 
PHI.
 
 
 
In
 
the
 
event
 
that
 
a
 
subject
 
revokes
 
authorization
 
to
 
collect
 
or
 
use
 
PHI,
 
the
 
investigator,
 
by
 
[CONTACT_5151],
 
retains
 
the
 
ability
 
to
 
use
 
all
 
information
 
collected
 
prior
 
to
 
the
 
revocation
 
of
 
subject
 
authorization.
  
For
 
subjects
 
that
 
have
 
revoked
 
authorization
 
to
 
collect
 
or
 
use
 
PHI,
 
attempts
 
should
 
be
 
made
 
to
 
obtain
 
permission
 
to
 
collect
 
at
 
least
 
vital
 
status
 
(i.e.
 
that
 
the
 
subject
 
is
 
alive)
 
at
 
the
 
end
 
of
 
their
 
scheduled
 
study
 
period.
 
 
Information
 
about
 
study
 
subjects
 
will
 
be
 
kept
 
confidential
 
and
 
managed
 
according
 
to
 
the
 
requirements
 
of
 
the
 
Health
 
Insurance
 
Portability
 
and
 
Accountability
 
Act
 
of
 
1996
 
(HIPAA).
  
Those
 
regulations
 
require
 
a
 
signed
 
subject
 
authorization
 
informing
 
the
 
subject
 
of
 
the
 
following:
 
 
â—
 
What
 
protected
 
health
 
information
 
(PHI)
 
will
 
be
 
collected
 
from
 
subjects
 
in
 
this
 
study
 
â—
 
Who
 
will
 
have
 
access
 
to
 
that
 
information
 
and
 
why
 
â—
 
Who
 
will
 
use
 
or
 
disclose
 
that
 
information
 
â—
 
The
 
rights
 
of
 
a
 
research
 
subject
 
to
 
revoke
 
their
 
authorization
 
for
 
use
 
of
 
their
 
PHI.
 
 
 
In
 
the
 
event
 
that
 
a
 
subject
 
revokes
 
authorization
 
to
 
collect
 
or
 
use
 
PHI,
 
the
 
investigator,
 
by
 
[CONTACT_5151],
 
retains
 
the
 
ability
 
to
 
use
 
all
 
information
 
collected
 
prior
 
to
 
the
 
revocation
 
of
 
subject
 
authorization.
 
 
Wherever
 
feasible,
 
identifiers
 
will
 
be
 
removed
 
from
 
study-related
 
information.
 
Computer-based
 
files
 
will
 
only
 
be
 
made
 
available
 
to
 
personnel
 
involved
 
in
 
the
 
study
 
through
 
the
  
use
 
of
 
access
 
privileges
 
and
 
passwords.
 
Precautions
 
are
 
in
 
place
 
to
 
ensure
 
the
 
data
 
is
 
secure
 
by
 
[CONTACT_510095].
 
Participants
 
and
 
screened
 
respondents
 
names
 
and
 
contact
 
[CONTACT_510096]:
 
(1)
 
contact
 
[CONTACT_510097];
 
(2)
 
re-contact
 
[CONTACT_510098];
 
and
 
(3)
 
re-contact
 
[CONTACT_510099].
 
Participants
 
will
 
be
 
informed
 
that
 
this
 
research
 
is
 
covered
 
by
 
a
 
Certiï¬cate
 
of
 
Conï¬dentiality
 
from
 
the
 
National
 
Institutes
 
of
 
Health.
 
This
 
means
 
that
 
the
 
researchers
 
cannot
 
release
 
or
 
use
 
information,
 
documents,
 
or
 
samples
 
that
 
may
 
identify
 
the
 
participant
 
in
 
any
 
action
 
or
 
suit
 
unless
 
the
 
participant
 
approves.
 
Authorities
 
also
 
cannot
 
provide
 
any
 
information,
 
documents,
 
or
 
samples
 
from
 
this
 
study
 
as
 
evidence
 
unless
 
the
 
participant
 
has
 
agreed.
 
This
 
V2025-[ADDRESS_659443]
 
subpoena.
  
Participants
 
will
 
also
 
be
 
informed
 
that
 
no
 
data
 
will
 
become
 
part
 
of
 
a
 
participant's
 
permanent
 
record
 
outside
 
of
 
the
 
Communication
 
Neuroscience
 
Lab,
 
such
 
as
 
employment
 
records
 
or
 
academic
 
records.
 
There
 
are
 
no
 
repercussions
 
of
 
participation/non
 
participation
 
for
 
Penn-afï¬liated
 
staff
 
or
 
students.
 
Participants
 
will
 
be
 
given
 
the
 
opportunity
 
to
 
opt
 
out
 
of
 
having
 
their
 
location
 
history
 
from
 
before
 
the
 
study
 
period
 
used
 
for
 
research
 
purposes,
 
other
 
than
 
for
 
the
 
purpose
 
of
 
establishing
 
study
 
eligibility
 
(see
 
opt-out
 
section
 
of
 
the
 
screening
 
B
 
consent
 
form).
 
 
8.[ADDRESS_659444]
 
participant
 
data.
  
We
 
review
 
these
 
by
 
[CONTACT_510100],
 
below:
 
â—
 
GENERAL:
  
All
 
information
 
collected
 
through
 
this
 
study
 
will
 
be
 
treated
 
as
 
strictly
 
conï¬dential.
 
Identifying
 
information
 
will
 
be
 
removed
 
from
 
the
 
data
 
as
 
much
 
as
 
possible
 
and
 
will
 
be
 
accessible
 
only
 
to
 
study
 
staff.
 
Data
 
that
 
is
 
de-identiï¬ed
 
will
 
be
 
coded
 
using
 
this
 
studyâ€™s
 
dual
 
ID
 
system:
 
Survey
 
A
 
automatically
 
assigns
 
a
 
RedCap
 
record
 
ID
 
number
 
to
 
each
 
screen
 
respondent
 
who
 
expresses
 
interest
 
in
 
participating.
 
This
 
number
 
is
 
different
 
from
 
the
 
study
 
ID
 
number,
 
which
 
is
 
only
 
assigned
 
to
 
enrolled
 
participants
 
(those
 
who
 
have
 
signed
 
the
 
full
 
electronic
 
informed
 
consent
 
on
 
RedCap
 
that
 
begins
 
Session
 
1).
  
 
â—
 
GREENPHIRE:
 
In
 
order
 
to
 
pay
 
participants
 
through
 
the
 
Greenphire
 
ClinCard
 
system,
 
we
 
will
 
be
 
required
 
to
 
enter
 
their
 
information
 
(required:
 
name,
 
date
 
of
 
birth,
 
address,
 
and
 
Social
 
Security
 
Number;
 
optional:
 
email
 
address
 
and/or
 
cell
 
phone
 
number
 
for
 
notiï¬cations).
 
For
 
more
 
information
 
on
 
this
 
system,
 
please
 
see
 
https://www.ï¬nance.upenn.edu/wp-content/uploads/Greenphire-Clincard-Human-Subject-Paym
ents.pdf.
 
 
â—
 
REDCAP:
 
RedCap
 
is
 
an
 
online
 
database
 
system
 
and
 
survey
 
platform:
 
https://ascRedCap.asc.upenn.edu/.
 
Access
 
to
 
the
 
RedCap
 
database
 
will
 
only
 
be
 
provided
 
to
 
authorized
 
study
 
staff
 
included
 
in
 
this
 
IRB
 
application.
 
Screen
 
A
 
will
 
collect
 
identiï¬able
 
information
 
(names,
 
phone
 
numbers,
 
and
 
e-mail
 
addresses)
 
through
 
a
 
RedCap
 
(or
 
BuildClinical)
 
survey.
 
Information
 
collected
 
via
 
BuildClinical
 
will
 
be
 
transferred
 
securely
 
to
 
RedCap.
 
Eligible
 
participants
 
will
 
be
 
automatically
 
identiï¬ed
 
through
 
a
 
built-in
 
reporting
 
feature
 
on
 
the
 
RedCap
 
database
 
(i.e.,
 
there
 
will
 
be
 
no
 
need
 
to
 
download
 
identiï¬able
 
data
 
from
 
RedCap
 
on
 
a
 
regular
 
basis).
 
RedCap
 
will
 
serve
 
as
 
the
 
location
 
for
 
linking
 
categories
 
of
 
subject
 
identiï¬ers
 
and
 
subject
 
names.
 
Electronic
 
consents
 
for
 
Screen
 
B,
 
the
 
main
 
study
 
(at
 
the
 
beginning
 
of
 
Online
 
Session
 
1),
 
and
 
the
 
optional
 
fMRI
 
Session
 
(after
 
completion
 
of
 
Online
 
Session
 
3)
 
will
 
also
 
be
 
recorded
 
and
 
stored
 
using
 
RedCap.
 
For
 
participants
 
who
 
complete
 
the
 
optional
 
fMRI
 
session,
 
results
 
of
 
the
 
urine
 
drug
 
screen
 
and
 
drug
 
use
 
questions
 
will
 
be
 
recorded
 
in
 
RedCap.
 
â—
 
BUILDCLINICAL:
 
BuildClinical
 
is
 
a
 
data-driven
 
software
 
platform
 
that
 
helps
 
academic
 
researchers
 
recruit
 
participants
 
for
 
research
 
studies
 
more
 
efï¬ciently
 
using
 
social
 
media,
 
software,
 
and
 
machine
 
learning.
 
BuildClinical
 
has
 
worked
 
with
 
IRBs
 
in
 
the
 
[LOCATION_003]
 
to
 
ensure
 
they
 
adhere
 
to
 
all
 
the
 
appropriate
 
guidelines
 
and
 
procedures.
 
They
 
utilize
 
study-speciï¬c
 
advertisements
 
to
 
engage
 
participants
 
on
 
digital
 
platforms
 
such
 
as
 
Facebook,
 
Google,
 
WebMD,
 
etc.,
 
and
 
redirect
 
them
 
to
 
a
 
study-speciï¬c
 
landing
 
page
 
should
 
they
 
click
 
it.
 
On
 
the
 
landing
 
page,
 
the
 
person
 
can
 
complete
 
an
 
online
 
pre-screen
 
questionnaire
 
that
 
gets
 
routed
 
into
 
BuildClinical's
 
platform.
 
BuildClinical's
 
Secure
 
Socket
 
Layer
 
(SSL)
 
software,
 
which
 
encrypts
 
all
 
inputted
 
information,
 
keeps
 
information
 
private
 
and
 
HIPAA
 
compliant.
 
BuildClinicals
 
backend
 
servers
 
are
 
stored
 
in
 
the
 
[LOCATION_003]
 
at
 
some
 
of
 
the
 
most
 
secure
 
data
 
centers
 
in
 
the
 
world.
 
â—
 
PARTICIPANT
 
CONTACT.
 
Participants
 
will
 
be
 
provided
 
with
 
the
 
phone
 
number
 
of
 
the
 
study
 
Google
 
Voice
 
account
 
and
 
the
 
study
 
GMail
 
address,
 
both
 
of
 
which
 
exist
 
within
 
the
 
labâ€™s
 
V2025-[ADDRESS_659445]
 
as
 
needed.
 
Account
 
passwords
 
are
 
shared
 
only
 
with
 
members
 
of
 
the
 
study
 
team.
  
 
â—
 
QUALTRICS:
 
Only
 
authorized
 
study
 
staff
 
will
 
be
 
granted
 
access
 
to
 
Qualtrics
 
surveys.
 
Survey
 
data
 
that
 
are
 
collected
 
through
 
Qualtrics
 
will
 
be
 
coded
 
with
 
a
 
study
 
identiï¬er.
 
Qualtrics
 
will
 
contain
 
a
 
link
 
between
 
email
 
addresses
 
and
 
study
 
identiï¬ers
 
for
 
creation
 
of
 
survey
 
distribution
 
links.
 
Qualtrics
 
surveys
 
will
 
not
 
contain
 
identiï¬able
 
data,
 
other
 
than
 
indirect
 
identiï¬ers
 
that
 
could
 
be
 
gleaned
 
upon
 
extensive
 
analysis
 
of
 
the
 
ï¬les
 
[photographs
 
and
 
geolocation
 
data]
 
that
 
participants
 
may
 
submit.
 
 
â—
 
LIFEDATA:
 
LifeData
 
is
 
a
 
third-party
 
tool
 
for
 
collecting
 
ecological
 
momentary
 
assessments
 
(EMA)
 
through
 
their
 
proprietary
 
RealLife
 
Exp
 
smartphone
 
application,
 
(https://www.lifedatacorp.com/mobile-app/).
 
developed
 
by
 
[CONTACT_510101]
 
(1)
 
responses
 
to
 
EMA
 
and
 
(2)
 
pi[INVESTIGATOR_510066].
 
The
 
app
 
does
 
not
 
require
 
any
 
identiï¬able
 
information;
 
all
 
data
 
collected
 
and
 
stored
 
by
 
[CONTACT_510102]
 
a
 
unique,
 
LifeData-generated
 
user
 
number.
 
 
â—
 
GOOGLE
 
MAPS:
 
Geolocation
 
data
 
will
 
be
 
collected
 
through
 
the
 
Google
 
Maps
 
app
 
and
 
Google
 
Timeline,
 
which
 
is
 
Googleâ€™s
 
location
 
tracking
 
service.
 
These
 
apps
 
might
 
already
 
be
 
active
 
on
 
some
 
participantsâ€™
 
phones
 
as
 
they
 
come
 
pre-installed
 
on
 
Android
 
phones.
 
If
 
approved
 
by
 
[CONTACT_510103],
 
Google
 
Maps
 
automatically
 
tracks
 
geolocation.
 
Google
 
will
 
be
 
able
 
to
 
access
 
and
 
use
 
the
 
mobility
 
data
 
collected
 
through
 
these
 
apps
 
per
 
their
 
data
 
agreement
 
with
 
the
 
user.
 
The
 
data
 
can
 
be
 
downloaded
 
by
 
[CONTACT_510104]
 
a
 
.json
 
or
 
.kml
 
ï¬le
 
which
 
includes
 
all
 
location
 
data
 
collected
 
by
 
[CONTACT_54834].
 
Participants
 
will
 
have
 
the
 
option
 
to
 
upload
 
their
 
location
 
data
 
via
 
Qualtrics
 
survey
 
or
 
PennBox.
 
This
 
downloaded
 
ï¬le
 
will
 
be
 
what
 
the
 
participants
 
submit
 
as
 
part
 
of
 
Screen
 
B
 
and
 
Sessions
 
2
 
and
 
3.
 
If
 
the
 
participant
 
opts
 
out
 
of
 
providing
 
their
 
location
 
history
 
from
 
before
 
the
 
study
 
period,
 
other
 
than
 
for
 
the
 
purpose
 
of
 
establishing
 
study
 
eligibility
 
(see
 
opt-out
 
section
 
of
 
the
 
main
 
study
 
consent
 
form),
 
all
 
data
 
which
 
was
 
collected
 
by
 
[CONTACT_510105]
 
1
 
and
 
Session
 
3
 
will
 
not
 
be
 
included
 
in
 
data
 
analysis,
 
other
 
than
 
for
 
the
 
purpose
 
of
 
establishing
 
study
 
eligibility.
  
 
â—
 
fMRI
 
DATA:
 
Neuroimaging
 
data
 
are
 
collected
 
at
 
scanners
 
located
 
on
 
Penn's
 
campus.
 
Imaging
 
data
 
is
 
standardly
 
stored
 
and
 
archived
 
on
 
(1)
 
a
 
secured,
 
password
 
protected
 
computer
 
located
 
at
 
the
 
scanner
 
site,
 
which
 
is
 
only
 
accessible
 
with
 
specific
 
access
 
rights,
 
and
 
(2)
 
on
 
Flywheel,
 
a
 
cloud-based
 
research
 
platform,
 
only
 
accessible
 
with
 
specific
 
access
 
rights.
 
Data
 
for
 
this
 
study
 
will
 
additionally
 
be
 
stored
 
on
 
the
 
ASC
 
server
 
(details
 
below).
 
 
â—
 
ASC
 
SERVER:
 
The
 
study
 
team
 
will
 
store
 
the
 
submitted
 
location
 
data
 
ï¬les
 
and
 
neuroimaging
 
data,
 
tagged
 
with
 
the
 
participant's
 
study
 
ID,
 
on
 
a
 
secure
 
server
 
that
 
is
 
maintained
 
by
 
[CONTACT_510106]
 
(ASC)
 
and
 
is
 
accessible
 
only
 
to
 
the
 
study
 
team
 
(including
 
approved
 
collaborators
 
at
 
New
 
York
 
University,
 
as
 
detailed
 
in
 
the
 
Data
 
Disclosure
 
section).
 
As
 
this
 
server
 
is
 
our
 
most
 
secure
 
platform
 
for
 
data
 
storage,
 
it
 
may
 
also
 
serve
 
as
 
a
 
back-up
 
location
 
for
 
data
 
that
 
is
 
collected
 
by
 
[INVESTIGATOR_1238]/or
 
stored
 
on
 
any
 
of
 
the
 
platforms
 
mentioned
 
in
 
this
 
section.
 
 
â—
 
PENNBOX:
 
PennBox
 
(aka
 
Penn+Box;
 
http://box.upenn.edu/)
 
is
 
a
 
cloud-based
 
collaboration
 
service
 
for
 
securely
 
managing
 
and
 
sharing
 
ï¬les
 
and
 
folders
 
within
 
the
 
Penn
 
community
 
and
 
externally.
 
Files
 
containing
 
coded
 
data,
 
such
 
as
 
EMA
 
data
 
and
 
survey
 
responses,
 
will
 
be
 
stored
 
on
 
PennBox
 
in
 
folders
 
that
 
are
 
only
 
shared
 
with
 
the
 
individuals
 
mentioned
 
in
 
the
 
Study
 
Personnel
 
and
 
Data
 
Disclosure
 
sections
 
of
 
this
 
protocol.
 
Any
 
ï¬les
 
on
 
PennBox
 
that
 
contain
 
identiï¬able
 
data
 
will
 
be
 
stored
 
in
 
a
 
separate
 
folder
 
and
 
will
 
be
 
password-protected
 
for
 
an
 
additional
 
level
 
of
 
security.
  
 
â—
 
STUDY
 
LOGISTICS:
 
We
 
will
 
keep
 
track
 
of
 
participants'
 
study
 
progress
 
through
 
a
 
spreadsheet
 
logging
 
study
 
appointments
 
and
 
the
 
completion
 
of
 
the
 
various
 
measures.
 
This
 
spreadsheet
 
will
 
be
 
coded
 
by
 
[CONTACT_510107]ï¬ers
 
and
 
study
 
staff
 
is
 
trained
 
to
 
not
 
include
 
any
 
personally
 
identiï¬able
 
information
 
(e.g.,
 
names,
 
emails,
 
phone
 
numbers)
 
in
 
this
 
spreadsheet.
 
V2025-[ADDRESS_659446],
 
Qualtrics,
 
RedCap,
 
and/or
 
Box
 
in
 
a
 
manner
 
such
 
that
 
it
 
is
 
only
 
accessible
 
to
 
authorized
 
study
 
staff.
 
The
 
studyâ€™s
 
Google
 
account
 
will
 
also
 
be
 
associated
 
with
 
a
 
study
 
calendar
 
which
 
will
 
include
 
information
 
about
 
study
 
appointments.
 
All
 
appointments
 
will
 
be
 
coded
 
by
 
[CONTACT_510108]ï¬able
 
information.
 
Only
 
Communication
 
Neuroscience
 
Lab
 
members
 
and
 
collaborators
 
will
 
have
 
access
 
to
 
this
 
calendar.
 
We
 
may
 
use
 
a
 
booking
 
system
 
such
 
as
 
https://simplybook.me
 
or
 
calendly
 
to
 
allow
 
participants
 
to
 
sign
 
up
 
for
 
a
 
time
 
for
 
their
 
intake
 
call.
 
Participants
 
will
 
have
 
the
 
option
 
to
 
include
 
their
 
contact
 
[CONTACT_510109],
 
but
 
we
 
will
 
explicitly
 
recommend
 
that
 
they
 
not
 
do
 
so,
 
as
 
sharing
 
contact
 
[CONTACT_510110]
 
a
 
third-party
 
platform
 
can
 
incur
 
minimal
 
additional
 
risks
 
to
 
conï¬dentiality,
 
and
 
if
 
they
 
choose
 
to
 
include
 
their
 
contact
 
[CONTACT_3031],
 
they
 
accept
 
that
 
risk.
 
In
 
addition,
 
some
 
of
 
the
 
systems
 
and
 
services
 
we
 
use
 
(such
 
as
 
BuildClinical
 
and
 
e-Ship)
 
may
 
send
 
non-optional
 
notiï¬cation
 
emails
 
to
 
staff
 
Penn
 
or
 
GSuite
 
email
 
accounts
 
that
 
include
 
participant
 
contact
 
[CONTACT_3031]
 
(such
 
as
 
name
 
[CONTACT_510116]).
 
Those
 
notiï¬cation
 
emails
 
will
 
be
 
deleted
 
from
 
all
 
staff
 
accounts
 
immediately,
 
but
 
will
 
be
 
saved
 
for
 
documentation
 
purposes
 
on
 
the
 
study
 
email
 
account,
 
which
 
already
 
contains
 
participant
 
information
 
(for
 
contact
 
[CONTACT_158874]).
 
 
9
 
Study
 
Monitoring,
 
Auditing,
 
and
 
Inspecting
 
9.1
 
Study
 
Monitoring
 
Plan
 
 
The
 
study
 
PI
 
[INVESTIGATOR_510067],
 
in
 
collaboration
 
with
 
the
 
Research
 
Director.
 
9.2
 
Auditing
 
and
 
Inspecting
 
The
 
investigator
 
will
 
permit
 
study-related
 
monitoring,
 
audits,
 
and
 
inspections
 
by
 
[CONTACT_510111]/IRB,
 
the
 
sponsor,
 
government
 
regulatory
 
bodies,
 
and
 
University
 
compliance
 
and
 
quality
 
assurance
 
groups
 
of
 
all
 
study
 
related
 
documents
 
(e.g.
 
source
 
documents,
 
regulatory
 
documents,
 
data
 
collection
 
instruments,
 
study
 
data
 
etc.).
  
The
 
investigator
 
will
 
ensure
 
the
 
capability
 
for
 
inspections
 
of
 
applicable
 
study-related
 
facilities
 
(e.g.
 
pharmacy,
 
diagnostic
 
laboratory,
 
etc.).
 
 
10
 
Ethical
 
Considerations
 
10.1
 
Risks
 
 
â—
 
There
 
may
 
be
 
a
 
risk
 
of
 
unintentional
 
breach
 
of
 
conï¬dentiality,
 
but
 
we
 
will
 
take
 
all
 
necessary
 
steps
 
to
 
prevent
 
this
 
from
 
happening.
 
Internet
 
data
 
transfers
 
between
 
mobile
 
device
 
users
 
and
 
the
 
study
 
web-server
 
will
 
be
 
based
 
on
 
a
 
session
 
ID
 
unique
 
to
 
the
 
user
 
and
 
the
 
date
 
and
 
time
 
of
 
access.
 
All
 
information
 
collected
 
via
 
the
 
Internet
 
will
 
be
 
kept
 
secure
 
in
 
transit
 
using
 
the
 
Secure
 
Socket
 
Layer
 
(SSL)
 
protocol,
 
the
 
same
 
technology
 
used
 
to
 
encrypt
 
credit
 
card
 
numbers
 
during
 
transmission
 
over
 
the
 
Internet.
 
All
 
data
 
will
 
be
 
stored
 
in
 
a
 
database
 
subject
 
to
 
both
 
physical
 
and
 
electronic
 
protection.
 
 
â—
 
Past
 
literature
 
suggests
 
that
 
there
 
may
 
be
 
negative
 
consequences
 
of
 
increased
 
exposure
 
to
 
POST-marketing,
 
such
 
as
 
increased
 
difï¬culty
 
in
 
quitting
 
and
 
increased
 
craving
 
during
 
a
 
quit
 
attempt.
 
However,
 
our
 
manipulation
 
does
 
not
 
involve
 
a
 
quit
 
attempt,
 
and
 
does
 
not
 
go
 
beyond
 
a
 
level
 
of
 
POST-marketing
 
exposure
 
that
 
participants
 
may
 
be
 
expected
 
to
 
have
 
in
 
their
 
normal
 
daily
 
lives.
 
At
 
most,
 
participants
 
are
 
asked
 
to
 
enter
 
a
 
POST-marketing
 
store,
 
such
 
as
 
a
 
common
 
convenience
 
store,
 
once
 
per
 
day.
 
Thus,
 
the
 
study
 
design
 
poses
 
risk
 
to
 
participants
 
on
 
par
 
with
 
everyday
 
life.
  
 
â—
 
For
 
the
 
duration
 
of
 
the
 
COVID-19
 
pandemic,
 
entry
 
into
 
retail
 
stores
 
as
 
part
 
of
 
this
 
study
 
V2025-06
 

 
may
 
increase
 
participants'
 
risk
 
of
 
being
 
exposed
 
to
 
and
 
spreading
 
SARS-COV-2,
 
the
 
virus
 
that
 
causes
 
COVID-19
 
disease.
 
To
 
reduce
 
transmission
 
risks,
 
the
 
study
 
team
 
will
 
send
 
participants
 
KN95/KF94
 
or
 
N95
 
respi[INVESTIGATOR_13530]
 
(masks)
 
in
 
their
 
box
 
of
 
study
 
materials,
 
which
 
they
 
will
 
be
 
strongly
 
encouraged
 
to
 
wear
 
during
 
study-related
 
store
 
visits
 
(in
 
accordance
 
with
 
local
 
guidelines)
 
and
 
in
 
their
 
daily
 
life.
 
Participants
 
are
 
also
 
required
 
to
 
be
 
vaccinated
 
against
 
COVID-19.
 
â—
 
For
 
optional
 
fMRI
 
session
 
component:
 
Safety
 
concerns
 
in
 
MR
 
environment:
 
The
 
magnetic
 
field
 
of
 
the
 
MRI
 
environment
 
has
 
the
 
potential
 
to
 
cause
 
burns
 
or
 
bodily
 
injury
 
if
 
ferrous
 
metal
 
objects
 
are
 
implanted
 
in
 
the
 
body
 
or
 
if
 
personal
 
articles
 
containing
 
ferrous
 
material
 
are
 
brought
 
into
 
the
 
MR
 
environment.
 
Because
 
we
 
are
 
excluding
 
subjects
 
with
 
contraindications
 
for
 
MR
 
studies
 
(e.g.,
 
metallic
 
implants
 
such
 
as
 
pacemakers,
 
surgical
 
aneurysm
 
clips,
 
or
 
known
 
metal
 
fragments
 
embedded
 
in
 
the
 
body)
 
using
 
a
 
standard
 
screening
 
form,
 
the
 
risk
 
of
 
damage
 
due
 
to
 
implanted
 
metal
 
is
 
low.
 
Investigators
 
and
 
personnel
 
of
 
the
 
MRI
 
unit
 
have
 
extensive
 
experience
 
with
 
standard
 
safety
 
precautions,
 
including
 
safety
 
screening
 
on
 
paper
 
and
 
verbally
 
by
 
a
 
trained
 
technologist.
 
These
 
considerations
 
minimize
 
the
 
risk
 
of
 
accident
 
or
 
injury
 
in
 
the
 
MR
 
environment.
 
Psychological
 
discomfort
 
secondary
 
to
 
MRI
 
acquisition
 
may
 
occur
 
in
 
some
 
subjects
 
due
 
to
 
claustrophobia.
 
Claustrophobia
 
is
 
also
 
part
 
of
 
the
 
exclusion
 
criteria,
 
and
 
participants
 
are
 
informed
 
that
 
they
 
may
 
stop
 
the
 
study
 
at
 
any
 
time
 
without
 
consequences
 
to
 
them.
 
Risk
 
of
 
discomfort
 
due
 
to
 
fMRI
 
scanner
 
noise
 
will
 
be
 
minimized
 
by
 
[CONTACT_510112].
 
The
 
level
 
of
 
noise
 
is
 
not
 
great
 
enough
 
to
 
pose
 
a
 
health
 
risk,
 
with
 
or
 
without
 
earphones.
 
There
 
is
 
a
 
risk
 
that
 
the
 
magnetic
 
resonance
 
image
 
will
 
reveal
 
a
 
minor
 
or
 
significant
 
lesion
 
in
 
the
 
brain,
 
e.g.
 
a
 
tumor,
 
previously
 
unknown
 
to
 
the
 
subject.
 
Structural
 
MRI
 
scans
 
will
 
not
 
be
 
read
 
by
 
a
 
radiologist,
 
and
 
subjects
 
will
 
be
 
informed
 
of
 
this.
 
No
 
diagnostic
 
or
 
clinical
 
information
 
will
 
be
 
provided,
 
and
 
participants
 
will
 
be
 
informed
 
of
 
this
 
before
 
consenting
 
to
 
participate.
 
We
 
exclude
 
subjects
 
with
 
contraindications
 
for
 
MR
 
studies
 
(e.g.,
 
metallic
 
implants
 
such
 
as
 
pacemakers,
 
surgical
 
aneurysm
 
clips,
 
or
 
known
 
metal
 
fragments
 
embedded
 
in
 
the
 
body)
 
using
 
a
 
standard
 
screening
 
form.
 
Investigators
 
and
 
personnel
 
of
 
the
 
MRI
 
unit
 
have
 
extensive
 
experience
 
with
 
standard
 
safety
 
precautions,
 
including
 
safety
 
screening
 
on
 
paper
 
and
 
verbally
 
by
 
a
 
trained
 
technologist.
 
These
 
considerations
 
minimize
 
the
 
risk
 
of
 
accident
 
or
 
injury
 
in
 
the
 
MR
 
environment.
 
Claustrophobia
 
is
 
also
 
part
 
of
 
the
 
exclusion
 
criteria,
 
and
 
participants
 
are
 
informed
 
that
 
they
 
may
 
stop
 
the
 
study
 
at
 
any
 
time
 
without
 
consequences
 
to
 
them.
 
The
 
risk
 
of
 
discomfort
 
due
 
to
 
fMRI
 
scanner
 
noise
 
will
 
be
 
minimized
 
by
 
[CONTACT_510112].
 
Thus,
 
the
 
risk
 
of
 
discomfort
 
will
 
be
 
minimized.
 
Participants
 
will
 
be
 
provided
 
with
 
a
 
hand-squeezable
 
pneumatic
 
signaling
 
device
 
for
 
communicating
 
with
 
investigators
 
during
 
scanning
 
should
 
they
 
experience
 
intolerable
 
discomfort
 
of
 
any
 
kind.
 
10.[ADDRESS_659447]
 
point-of-sale
 
marketing
 
affects
 
their
 
smoking
 
behavior
 
and
 
decision-making
 
about
 
the
 
use
 
of
 
tobacco
 
products.
 
10.3
 
Risk
 
Benefit
 
Assessment
 
 
Given
 
the
 
minimal
 
risk
 
of
 
the
 
study
 
and
 
the
 
great
 
potential
 
beneï¬t
 
for
 
understanding
 
the
 
relationship
 
between
 
the
 
brain
 
and
 
behavior,
 
the
 
potential
 
beneï¬ts
 
to
 
society
 
outweigh
 
the
 
risks.
 
 
10.4
 
Informed
 
Consent
 
Process
 
/
 
HIPAA
 
Authorization
 
 
 
V2025-06
 

 
â—
 
SCREEN
 
B
 
CONSENT:
 
Screen
 
B
 
will
 
begin
 
with
 
a
 
consent
 
that
 
explains
 
the
 
purpose
 
and
 
nature
 
of
 
this
 
screening.
 
(See
 
ScreeningSurveyBConsent.docx)
 
To
 
continue
 
into
 
the
 
screening
 
survey,
 
participants
 
will
 
have
 
to
 
indicate
 
that
 
they
 
have
 
read
 
and
 
understood
 
this
 
consent.
 
This
 
includes
 
an
 
optional
 
section
 
that
 
gives
 
participants
 
the
 
opportunity
 
to
 
opt
 
out
 
of
 
having
 
their
 
location
 
history
 
from
 
before
 
the
 
study
 
period
 
used
 
for
 
data
 
analysis,
 
meaning
 
the
 
study
 
team
 
would
 
only
 
use
 
the
 
data
 
uploaded
 
in
 
this
 
survey
 
for
 
the
 
purpose
 
of
 
establishing
 
study
 
eligibility
 
(not
 
for
 
any
 
further
 
analysis
 
or
 
publication).
 
This
 
section
 
explicitly
 
states
 
that
 
declining
 
to
 
consent
 
to
 
analysis
 
of
 
their
 
full
 
history
 
does
 
not
 
preclude
 
participation
 
in
 
the
 
rest
 
of
 
the
 
study.
  
The
 
Screen
 
B
 
consent
 
also
 
explains
 
that
 
individuals
 
who
 
are
 
found
 
to
 
live
 
outside
 
of
 
the
 
speciï¬ed
 
study
 
area
 
or
 
are
 
not
 
fully
 
vaccinated
 
will
 
be
 
informed
 
that
 
they
 
are
 
ineligible
 
for
 
this
 
study,
 
and
 
that
 
the
 
study
 
team
 
will
 
delete
 
their
 
geolocation
 
data
 
and
 
provide
 
them
 
with
 
optional
 
instructions
 
for
 
turning
 
off
 
Google
 
Timeline
 
and
 
uninstalling
 
Google
 
Maps.
 
 
â—
 
FULL
 
STUDY
 
CONSENT:
 
If
 
eligible
 
following
 
screens
 
A
 
and
 
B,
 
participants
 
will
 
be
 
invited
 
to
 
consent
 
electronically
 
to
 
the
 
full
 
study.
 
Participants
 
will
 
read,
 
and
 
be
 
sent
 
a
 
PDF
 
version
 
of,
 
the
 
informed
 
consent
 
form
 
to
 
be
 
signed
 
electronically
 
(or
 
not).
 
Please
 
see
 
the
 
attached
 
ï¬le
 
for
 
the
 
content
 
of
 
the
 
consent
 
form
 
for
 
the
 
full
 
study.
 
Experimenters
 
will
 
talk
 
through
 
this
 
consent
 
form
 
with
 
participants
 
during
 
the
 
intake
 
call
 
and
 
will
 
answer
 
any
 
questions.
 
Consent
 
will
 
be
 
deemed
 
provided
 
if
 
after
 
reading
 
the
 
consent
 
document,
 
the
 
prospective
 
participant
 
electronically
 
signs
 
it
 
using
 
RedCaps
 
HIPAA
 
compliant
 
system
 
for
 
e-signature.
 
â—
 
OPTIONAL
 
fMRI
 
SESSION
 
CONSENT:
 
After
 
confirming
 
that
 
the
 
participant
 
meets
 
any
 
COVID-19
 
screening
 
requirements
 
(e.g.,
 
symptom
 
screen,
 
temperature
 
check),
 
at
 
the
 
in-person
 
session,
 
researchers
 
will
 
review
 
the
 
consent
 
document
 
with
 
participants.
 
Participants
 
will
 
provide
 
informed
 
consent
 
via
 
RedCap.
 
 
[ADDRESS_659448]
 
Stipends
 
or
 
Payments
 
Each
 
participant
 
can
 
earn
 
compensation
 
of
 
up
 
to
 
$500.[ADDRESS_659449]
 
by
 
[CONTACT_510113].
 
Some
 
participants
 
may
 
be
 
eligible
 
for
 
an
 
optional
 
in-person
 
fMRI
 
scan
 
session,
 
with
 
additional
 
compensation
 
of
 
$95,
 
paid
 
through
 
ClinCard.
  
Please
 
consult
 
the
 
compensation
 
schedule
 
(table)
 
below
 
for
 
detailed
 
descriptions
 
of
 
subject
 
compensation.
 
 
Conditions
 
1
 
&
 
2
 
=
 
Tobacco
 
and
 
Nontobacco
 
retailer
 
conditions
 
Condition
 
3
 
=
 
Control
 
 
KEY:
 
All
 
conditions
 
Cond.
 
1
 
&
 
2
 
Cond.
 
3
 
 
 
Period
 
of
 
task
 
Task
 
completed
 
Payment
 
Rate
 
Max
 
possibl 
e
 
Max
 
Total
 
STORE
 
Max
 
Total
 
CONTROL
 
V2025-06
 

 
Online
 
Session
 
1
 
Cumulative
 
payment
 
for
 
Screens
 
A
 
&
 
B,
 
initial
 
call,
 
and
 
Online
 
Session
 
1
 
$95
 
$95
 
at
 
Online
 
Session
 
1
 
$95
 
at
 
Online
 
Session
 
1
 
Baseline
 
(2
 
weeks)
 
EMA
 
response
 
$28/week
 
*
 
2
 
weeks
 
for
 
75%
 
compliance
 
$55
 
$90
 
at
 
Online
 
Session
 
2
 
$75
 
at
 
Online
 
Session
 
2
 
Online
 
Session
 
2
 
Session
 
2
 
$20
 
Intervention
 
(4
 
weeks)
 
Store
 
purchase
 
funds
 
(week
 
1)
 
$3/visit
 
*
 
5
 
visits/week
 
$15
 
Store
 
purchase
 
funds
 
(week
 
2)
 
$3/visit
 
*
 
5
 
visits/week
 
$15
 
$15
 
after
 
Intervention
 
Week
 
1
 
n/a
 
Store
 
purchase
 
funds
 
(week
 
3)
 
$3/visit
 
*
 
5
 
visits/week
 
$15
 
$15
 
after
 
Intervention
 
Week
 
2
 
n/a
 
Store
 
purchase
 
funds
 
(week
 
4)
 
$3/visit
 
*
 
5
 
visits/week
 
(cond.
 
1
 
or
 
2)
 
$15
 
$15
 
after
 
Intervention
 
Week
 
3
 
n/a
 
EMA
 
response
 
$28/week
 
*
 
4
 
weeks
 
for
 
75%
 
compliance
 
$110
 
$270
 
at
 
Online
 
Session
 
3
 
$330
 
at
 
Online
 
Session
 
3
 
Store
 
receipt
 
photographs
 
$5/receipt
 
*
 
20
 
receipts
 
(cond.
 
1
 
or
 
2)
 
$100
 
Weekly
 
survey
 
$2.50
 
each
 
for
 
completion
 
of
 
4
 
weekly
 
surveys
 
$10
 
Online
 
Session
 
3
 
Session
 
3
 
$20
 
Study
 
completion
 
$30
 
for
 
cond.
 
1
 
or
 
2
 
$190
 
for
 
cond.
 
3
 
$30
 
$190
 
 
 
 
 
 
 
 
 
 
Maximum
 
payment
 
for
 
completing
 
all
 
remote
 
tasks
 
$500
 
$500
 
$500
 
OPTIONAL
 
In-Person
 
Session
 
2-hour
 
session
  
(includes
 
1-hour
 
fMRI
 
scan)
 
$95
 
$95
 
at
 
the
 
optional
 
In-Person
 
Session
 
$95
 
at
 
the
 
optional
 
In-Person
 
Session
 
Maximum
 
total
 
payment
 
for
 
all
 
remote
 
AND
 
in-person
 
tasks
 
$595
 
$595
 
$595
 
 
V2025-06
 

 
 
12
 
Publication
 
Plan
 
 
This
 
study
 
will
 
be
 
conducted
 
in
 
accordance
 
with
 
the
 
following
 
publication
 
and
 
data
 
sharing
 
policies
 
and
 
regulations:
 
 
National
 
Institutes
 
of
 
Health
 
(NIH)
 
Public
 
Access
 
Policy,
 
which
 
ensures
 
that
 
the
 
public
 
has
 
access
 
to
 
the
 
published
 
results
 
of
 
NIH
 
funded
 
research.
 
It
 
requires
 
scientists
 
to
 
submit
 
final
 
peer-reviewed
 
journal
 
manuscripts
 
that
 
arise
 
from
 
NIH
 
funds
 
to
 
the
 
digital
 
archive
 
PubMed
 
Central
 
upon
 
acceptance
 
for
 
publication.
 
 
This
 
study
 
will
 
comply
 
with
 
the
 
NIH
 
Data
 
Sharing
 
Policy
 
and
 
Policy
 
on
 
the
 
Dissemination
 
of
 
NIH-Funded
 
Clinical
 
Trial
 
Information
 
and
 
the
 
Clinical
 
Trials
 
Registration
 
and
 
Results
 
Information
 
Submission
 
rule.
 
As
 
such,
 
this
 
trial
 
has
 
been
 
registered
 
at
 
ClinicalTrials.gov,
 
and
 
results
 
information
 
from
 
this
 
trial
 
will
 
be
 
submitted
 
to
 
ClinicalTrials.gov.
 
In
 
addition,
 
every
 
attempt
 
will
 
be
 
made
 
to
 
publish
 
results
 
in
 
peer-reviewed
 
journals.
 
 
 
Final
 
research
 
data,
 
with
 
all
 
identity-related
 
information
 
deleted
 
and
 
in
 
consultation
 
with
 
the
 
relevant
 
IRBs,
 
will
 
be
 
made
 
available
 
to
 
the
 
scientific
 
community
 
for
 
collaborative
 
research
 
with
 
members
 
of
 
the
 
study
 
team,
 
upon
 
request,
 
in
 
spreadsheet
 
format
 
for
 
all
 
non-imaging
 
data
 
and
 
in
 
NIFTI
 
format
 
for
 
fMRI
 
data.
  
These
 
data
 
will
 
be
 
shared
 
upon
 
request
 
in
 
consultation
 
with
 
relevant
 
IRBs
 
for
 
further
 
analysis
 
once
 
the
 
studyâ€™s
 
primary
 
results
 
have
 
been
 
published.
 
Qualified
 
investigators
 
who
 
wish
 
to
 
access
 
the
 
study
 
materials
 
will
 
be
 
able
 
to
 
complete
 
a
 
form
 
on
 
the
 
main
 
project
 
website,
 
which
 
describes
 
the
 
proposed
 
study
 
and
 
delineates
 
the
 
data
 
specifics
 
of
 
data
 
use.
  
The
 
requests
 
will
 
be
 
reviewed
 
and
 
approved
 
by
 
[CONTACT_510114].
 
Data
 
that
 
may
 
be
 
difficult
 
to
 
de-identify
 
(including
 
geolocation
 
data)
 
will
 
be
 
shared
 
at
 
an
 
aggregate
 
level,
 
with
 
restrictions
 
as
 
developed
 
in
 
consultation
 
with
 
the
 
IRB,
 
to
 
protect
 
participant
 
privacy.
 
The
 
requested
 
research
 
data
 
files
 
will
 
be
 
accompanied
 
by
 
a
 
description
 
of
 
variables
 
and
 
how
 
they
 
were
 
collected.
  
We
 
will
 
also
 
share
 
protocols
 
relevant
 
to
 
data
 
collection
 
procedures,
 
as
 
useful
 
and
 
in
 
consultation
 
with
 
other
 
interested
 
researchers.
 
Imaging
 
data
 
files
 
will
 
be
 
made
 
available
 
to
 
researchers
 
following
 
the
 
procedures
 
outlined
 
above
 
through
 
a
 
secure
 
file-sharing
 
interface
 
once
 
the
 
main
 
findings
 
have
 
been
 
published,
 
in
 
consultation
 
with
 
the
 
relevant
 
IRBs;
 
alternative
 
requests
 
regarding
 
format
 
of
 
imaging
 
data
 
will
 
also
 
be
 
considered
 
and
 
honored
 
to
 
the
 
extent
 
possible
 
within
 
practical
 
constraints.
 
Study
 
tasks
 
and
 
code
 
to
 
reproduce
 
analyses
 
will
 
be
 
made
 
available
 
on
 
the
 
Falk
 
Lab
 
GitHub
 
account
 
(https://github.com/cnlab/).
 
13
 
References
 
 
Summary
 
1.
 
Center
 
for
  
Public
 
Health
 
Systems
 
Science.
 
Point-of-sale
 
report
 
to
 
the
 
nation.
 
State
 
and
 
Community
 
Tobacco
  
Control
 
Research
 
2.
 
Kirchner,
 
T.
 
R.
 
et
 
al.
 
Geospatial
 
Exposure
 
to
 
Point-of-Sale
 
Tobacco.
 
AMEPRE
 
45,
  
379385
 
(2013).
 
 
3.
 
Wakefield,
 
M.,
 
Germain,
 
D.
 
&
 
Henriksen,
 
L.
 
The
 
effect
 
of
 
retail
 
cigarette
 
pack
  
displays
 
on
 
impulse
 
purchase.
 
Addiction
 
103,
 
322328
 
(2008).
 
 
4.
 
Jasinska,
 
A.
 
J.,
 
Stein,
 
E.
 
A.,
 
Kaiser,
 
J.,
  
Naumer,
 
M.
 
J.
 
&
 
Yalachkov,
 
Y.
 
Factors
 
modulating
 
neural
 
reactivity
 
to
 
drug
 
cues
 
in
 
addiction:
 
A
 
survey
  
of
 
human
 
neuroimaging
 
studies.
 
V2025-06
 

 
Neuroscience
 
&
 
Biobehavioral
 
Reviews
 
38,
 
116
 
(2014).
 
 
5.
 
Engelmann,
  
J.
 
M.
 
et
 
al.
 
Neural
 
substrates
 
of
 
smoking
 
cue
 
reactivity:
 
A
 
meta-analysis
 
of
 
fMRI
 
studies.
 
NeuroImage
  
60,
 
252262
 
(2012).
 
 
6.
 
Janes,
 
A.
 
C.
 
et
 
al.
 
Brain
 
Reactivity
 
to
 
Smoking
 
Cues
 
Prior
 
to
 
Smoking
 
Cessation
  
Predicts
 
Ability
 
to
 
Maintain
 
Tobacco
 
Abstinence.
 
BPS
 
67,
 
722729
 
(2010).
 
 
7.
 
McClernon,
 
F.
 
J.,
 
Kozink,
  
R.
 
V.,
 
Lutz,
 
A.
 
M.
 
&
 
Rose,
 
J.
 
E.
 
24-h
 
smoking
 
abstinence
 
potentiates
 
fMRI-BOLD
 
activation
 
to
  
smoking
 
cues
 
in
 
cerebral
 
cortex
 
and
 
dorsal
 
striatum.
 
Psychopharmacology
 
204,
 
2535
 
(2008).
 
 
8.
 
Bedi,
  
G.
 
et
 
al.
 
Incubation
 
of
 
Cue-Induced
 
Cigarette
 
Craving
 
During
 
Abstinence
 
in
 
Human
 
Smokers.
 
BPS
 
69,
  
708711
 
(2011).
 
 
 
Study
 
background
 
1.
 
US
 
Department
 
of
 
Health
 
and
 
Human
 
Services.
 
The
 
Health
 
Consequences
 
of
 
Smoking
 
-
 
50
 
Years
 
of
 
Progress:
 
A
 
Report
 
of
 
the
 
Surgeon
 
General.
 
(2014).
 
Available
 
at:
 
http://www.surgeongeneral.gov/library/reports/50-years-of-progress/50-years-of-progress-by-sec 
tion.html.
 
(Accessed:
 
31st
 
October
 
2016)
 
2.
 
National
 
Center
 
for
 
Chronic
 
Disease
 
Prevention
 
and
 
Health
 
Promotion
 
(US)
 
Office
 
on
 
Smoking
 
and
 
Health.
 
The
 
Health
 
Consequences
 
of
 
Smokingâ€”50
 
Years
 
of
 
Progress:
 
A
 
Report
 
of
 
the
 
Surgeon
 
General
.
 
(Centers
 
for
 
Disease
 
Control
 
and
 
Prevention
 
(US),
 
2014).
 
3.
 
Smoking,
 
C.
 
O.
 
on
 
&
 
Health.
 
Smoking
 
and
 
Tobacco
 
Use;
 
Fact
 
Sheet;
 
Tobacco-Related
 
Mortality.
 
4.
 
Federal
 
Trade
 
Commission.
 
Cigarette
 
Report
 
for
 
2011.
 
(2013).
 
Available
 
at:
 
<http://www.ftc.gov/sites/default/files/documents/reports/federal-trade-commissioncigarette-.
 
5.
 
Wakefield,
 
M.
 
A.
 
et
 
al.
 
Tobacco
 
industry
 
marketing
 
at
 
point
 
of
 
purchase
 
after
 
the
 
[ADDRESS_659450]
 
advertising
 
ban.
 
Am.
 
J.
 
Public
 
Health
 
92,
 
937â€“940
 
(2002).
 
6.
 
Henriksen,
 
L.
 
Comprehensive
 
tobacco
 
marketing
 
restrictions:
 
promotion,
 
packaging,
 
price
 
and
 
place.
 
Tob.
 
Control
 
21,
 
147â€“153
 
(2012).
 
7.
 
Truth
 
Initiative.
 
How
 
big
 
is
 
Big
 
Tobaccoâ€™s
 
marketing
 
budget?
 
Truth
 
Initiative
 
(2016).
 
Available
 
at:
 
https://truthinitiative.org/news/how-big-big-tobaccos-marketing-budget.
 
(Accessed:
 
6th
 
October
 
2017)
 
8.
 
Center
 
for
 
Public
 
Health
 
Systems
 
Science.
 
Point-of-Sale
 
Report
 
to
 
the
 
Nation:
 
The
 
Tobacco
 
Retail
 
and
 
Policy
 
Landscape.
 
(2014).
 
9.
 
Center
 
for
 
Public
 
Health
 
Systems
 
Science.
 
Point-of-Sale
 
Report
 
to
 
the
 
Nation:
 
The
 
Tobacco
 
Retail
 
and
 
Policy
 
Landscape.
 
(2014).
 
Available
 
at:
 
<http://www.legacyforhealth.org/content/download/.
 
10.
 
 
Feld,
 
A.
 
L.
 
How
 
to
 
Conduct
 
Store
 
Observations
 
of
 
Tobacco
 
Marketing
 
and
 
Products.
 
Prev.
 
Chronic
 
Dis.
 
13,
 
(2016).
 
11.
 
 
The
 
War
 
in
 
the
 
Store
 
â€“
 
Counter
 
Tobacco.
 
Available
 
at:
 
http://countertobacco.org/the-war-in-the-store/.
 
(Accessed:
 
1st
 
October
 
2017)
 
12.
 
 
[PDF]Evidence
 
brief:
 
Tobacco
 
point-of-sale
 
display
 
bans
 
-
 
eng
 
-
 
WHO/Europe.
 
13.
 
 
Kirchner,
 
T.
 
R.
 
et
 
al.
 
Geospatial
 
Exposure
 
to
 
Point-of-Sale
 
Tobacco.
 
Am.
 
J.
 
Prev.
 
Med.
 
45,
 
379â€“385
 
(2013).
 
14.
 
 
Kirchner,
 
T.
 
R.
 
et
 
al.
 
Individual
 
Mobility
 
Patterns
 
and
 
Real-time
 
Geo-spatial
 
Exposure
 
to
 
Point-of-sale
 
Tobacco
 
Marketing.
 
in
 
Proceedings
 
of
 
the
 
Conference
 
on
 
Wireless
 
Health
 
8:1â€“8:8
 
(ACM,
 
2012).
 
15.
 
 
Shiffman,
 
S.,
 
Stone,
 
A.
 
A.
 
&
 
Hufford,
 
M.
 
R.
 
Ecological
 
momentary
 
assessment.
 
Annu.
 
Rev.
 
Clin.
 
Psychol.
 
4,
 
1â€“32
 
(2008).
 
16.
 
 
Engelmann,
 
J.
 
M.
 
et
 
al.
 
Neural
 
substrates
 
of
 
smoking
 
cue
 
reactivity:
 
a
 
meta-analysis
 
of
 
fMRI
 
studies.
 
Neuroimage
 
60,
 
252â€“262
 
(2012).
 
17.
 
 
McClernon,
 
F.
 
J.,
 
Hiott,
 
F.
 
B.,
 
Huettel,
 
S.
 
A.
 
&
 
Rose,
 
J.
 
E.
 
Abstinence-Induced
 
Changes
 
in
 
V2025-06
 

 
Self-Report
 
Craving
 
Correlate
 
with
 
Event-Related
 
fMRI
 
Responses
 
to
 
Smoking
 
Cues.
 
Neuropsychopharmacology
 
30,
 
1940â€“1947
 
(2005).
 
18.
 
 
McClernon,
 
F.
 
J.
 
et
 
al.
 
Hippocampal
 
and
 
Insular
 
Response
 
to
 
Smoking-Related
 
Environments:
 
Neuroimaging
 
Evidence
 
for
 
Drug-Context
 
Effects
 
in
 
Nicotine
 
Dependence.
 
Neuropsychopharmacology
 
41,
 
877â€“885
 
(2016).
 
19.
 
 
Li,
 
L.
 
et
 
al.
 
Impact
 
of
 
point-of-sale
 
tobacco
 
display
 
bans:
 
findings
 
from
 
the
 
International
 
Tobacco
 
Control
 
Four
 
Country
 
Survey.
 
Health
 
Educ.
 
Res.
 
28,
 
898â€“910
 
(2013).
 
20.
 
 
Henriksen,
 
L.,
 
Schleicher,
 
N.
 
C.,
 
Feighery,
 
E.
 
C.
 
&
 
Fortmann,
 
S.
 
P.
 
A
 
longitudinal
 
study
 
of
 
exposure
 
to
 
retail
 
cigarette
 
advertising
 
and
 
smoking
 
initiation.
 
Pediatrics
 
126,
 
232â€“238
 
(2010).
 
21.
 
 
Quinn,
 
C.,
 
Lewis,
 
S.,
 
Edwards,
 
R.
 
&
 
McNeill,
 
A.
 
Economic
 
evaluation
 
of
 
the
 
removal
 
of
 
tobacco
 
promotional
 
displays
 
in
 
Ireland.
 
Tob.
 
Control
 
20,
 
151â€“155
 
(2011).
 
22.
 
 
Robertson,
 
L.,
 
McGee,
 
R.,
 
Marsh,
 
L.
 
&
 
Hoek,
 
J.
 
A
 
systematic
 
review
 
on
 
the
 
impact
 
of
 
point-of-sale
 
tobacco
 
promotion
 
on
 
smoking.
 
Nicotine
 
Tob.
 
Res.
 
17,
 
2â€“17
 
(2015).
 
23.
 
 
Burton,
 
S.,
 
Clark,
 
L.
 
&
 
Jackson,
 
K.
 
The
 
association
 
between
 
seeing
 
retail
 
displays
 
of
 
tobacco
 
and
 
tobacco
 
smoking
 
and
 
purchase:
 
findings
 
from
 
a
 
diary-style
 
survey.
 
Addiction
 
107,
 
169â€“175
 
(2012).
 
24.
 
 
Carter,
 
O.
 
B.
 
J.,
 
Phan,
 
T.
 
&
 
Mills,
 
B.
 
W.
 
Impact
 
of
 
a
 
point-of-sale
 
tobacco
 
display
 
ban
 
on
 
smokersâ€™
 
spontaneous
 
purchases:
 
comparisons
 
from
 
postpurchase
 
interviews
 
before
 
and
 
after
 
the
 
ban
 
in
 
Western
 
Australia.
 
Tob.
 
Control
 
24,
 
e81â€“6
 
(2015).
 
25.
 
 
Carter,
 
O.
 
B.
 
J.,
 
Mills,
 
B.
 
W.
 
&
 
Donovan,
 
R.
 
J.
 
The
 
effect
 
of
 
retail
 
cigarette
 
pack
 
displays
 
on
 
unplanned
 
purchases:
 
results
 
from
 
immediate
 
postpurchase
 
interviews.
 
Tob.
 
Control
 
18,
 
218â€“221
 
(2009).
 
26.
 
 
Wakefield,
 
M.,
 
Germain,
 
D.
 
&
 
Henriksen,
 
L.
 
The
 
effect
 
of
 
retail
 
cigarette
 
pack
 
displays
 
on
 
impulse
 
purchase.
 
Addiction
 
103,
 
322â€“328
 
(2008).
 
27.
 
 
Siahpush,
 
M.
 
et
 
al.
 
The
 
association
 
of
 
exposure
 
to
 
point-of-sale
 
tobacco
 
marketing
 
with
 
quit
 
attempt
 
and
 
quit
 
success:
 
Results
 
from
 
a
 
prospective
 
study
 
of
 
smokers
 
in
 
the
 
United
 
States.
 
Int.
 
J.
 
Environ.
 
Res.
 
Public
 
Health
 
13,
 
203
 
(2016).
 
28.
 
 
Siahpush,
 
M.
 
et
 
al.
 
The
 
association
 
of
 
point-of-sale
 
cigarette
 
marketing
 
with
 
cravings
 
to
 
smoke:
 
results
 
from
 
a
 
cross-sectional
 
population-based
 
study.
 
Tob.
 
Control
 
25,
 
402â€“405
 
(2016).
 
29.
 
 
Henriksen,
 
L.
 
et
 
al.
 
Is
 
adolescent
 
smoking
 
related
 
to
 
the
 
density
 
and
 
proximity
 
of
 
tobacco
 
outlets
 
and
 
retail
 
cigarette
 
advertising
 
near
 
schools?
 
Prev.
 
Med.
 
47,
 
210â€“214
 
(2008).
 
30.
 
 
Lipperman-Kreda,
 
S.
 
et
 
al.
 
Density
 
and
 
proximity
 
of
 
tobacco
 
outlets
 
to
 
homes
 
and
 
schools:
 
relations
 
with
 
youth
 
cigarette
 
smoking.
 
Prev.
 
Sci.
 
15,
 
738â€“744
 
(2014).
 
31.
 
 
Pearce,
 
J.,
 
Hiscock,
 
R.,
 
Moon,
 
G.
 
&
 
Barnett,
 
R.
 
The
 
neighbourhood
 
effects
 
of
 
geographical
 
access
 
to
 
tobacco
 
retailers
 
on
 
individual
 
smoking
 
behaviour.
 
J.
 
Epi[INVESTIGATOR_5541].
 
Community
 
Health
 
63,
 
69â€“77
 
(2009).
 
32.
 
 
Cantrell,
 
J.
 
et
 
al.
 
The
 
impact
 
of
 
the
 
tobacco
 
retail
 
outlet
 
environment
 
on
 
adult
 
cessation
 
and
 
differences
 
by
 
[CONTACT_510115].
 
Addiction
 
110,
 
152â€“161
 
(2015).
 
33.
 
 
Reitzel,
 
L.
 
R.
 
et
 
al.
 
The
 
effect
 
of
 
tobacco
 
outlet
 
density
 
and
 
proximity
 
on
 
smoking
 
cessation.
 
Am.
 
J.
 
Public
 
Health
 
101,
 
315â€“320
 
(2011).
 
34.
 
 
Chaiton,
 
M.
 
O.,
 
Mecredy,
 
G.
 
&
 
Cohen,
 
J.
 
Tobacco
 
retail
 
availability
 
and
 
risk
 
of
 
relapse
 
among
 
smokers
 
who
 
make
 
a
 
quit
 
attempt:
 
a
 
population-based
 
cohort
 
study.
 
Tob.
 
Control
 
(2017).
 
doi:
10.1136/tobaccocontrol-2016-053490
 
35.
 
 
Kim,
 
A.
 
E.
 
et
 
al.
 
Influence
 
of
 
point-of-sale
 
tobacco
 
displays
 
and
 
graphic
 
health
 
warning
 
signs
 
on
 
adults:
 
evidence
 
from
 
a
 
virtual
 
store
 
experimental
 
study.
 
Am.
 
J.
 
Public
 
Health
 
104,
 
888â€“895
 
(2014).
 
36.
 
 
State
 
Tobacco
 
Cessation
 
Coverage.
 
Available
 
at:
 
http://slati.lung.org/slati/.
 
(Accessed:
 
19th
 
September
 
2017)
 
37.
 
 
Tobacco
 
Products
 
Tax
 
Licenses
 
Current
 
Revenue
 
|
 
PA
 
Open
 
Data
 
Portal.
 
Available
 
at:
 
https://data.pa.gov/Licenses-Certificates/Tobacco-Products-Tax-Licenses-Current-Revenue/ut72 
-sft8.
 
(Accessed:
 
7th
 
October
 
2017)
 
V2025-06
 

 
38.
 
 
Kirchner,
 
T.
 
R.
 
et
 
al.
 
Geospatial
 
Exposure
 
to
 
Point-of-Sale
 
Tobacco.
 
Am.
 
J.
 
Prev.
 
Med.
 
45,
 
379â€“385
 
(2013).
 
39.
 
 
Shadel,
 
W.
 
G.,
 
Martino,
 
S.
 
C.,
 
Setodji,
 
C.
 
&
 
Scharf,
 
D.
 
Exposure
 
to
 
pro-smoking
 
media
 
in
 
college
 
students:
 
does
 
type
 
of
 
media
 
channel
 
differentially
 
contribute
 
to
 
smoking
 
risk?
 
Ann.
 
Behav.
 
Med.
 
45,
 
387â€“392
 
(2013).
 
40.
 
 
Shiffman,
 
S.
 
Ecological
 
momentary
 
assessment
 
(EMA)
 
in
 
studies
 
of
 
substance
 
use.
 
Psychol.
 
Assess.
 
21,
 
486â€“497
 
(2009).
 
41.
 
 
Berkman,
 
E.
 
T.,
 
Dickenson,
 
J.,
 
Falk,
 
E.
 
B.
 
&
 
Lieberman,
 
M.
 
D.
 
Using
 
SMS
 
text
 
messaging
 
to
 
assess
 
moderators
 
of
 
smoking
 
reduction:
 
Validating
 
a
 
new
 
tool
 
for
 
ecological
 
measurement
 
of
 
health
 
behaviors.
 
Health
 
Psychol.
 
30,
 
186â€“194
 
(2011).
 
42.
 
 
Konrath,
 
S.
 
et
 
al.
 
Can
 
Text
 
Messages
 
Increase
 
Empathy
 
and
 
Prosocial
 
Behavior?
 
The
 
Development
 
and
 
Initial
 
Validation
 
of
 
Text
 
to
 
Connect.
 
PLoS
 
One
 
10,
 
e0137585
 
(2015).
 
43.
 
 
Carter,
 
B.
 
L.
 
&
 
Tiffany,
 
S.
 
T.
 
Meta-analysis
 
of
 
cue-reactivity
 
in
 
addiction
 
research.
 
Addiction
 
94,
 
327â€“340
 
(1999).
 
44.
 
 
Tiffany,
 
S.
 
T.
 
A
 
cognitive
 
model
 
of
 
drug
 
urges
 
and
 
drug-use
 
behavior:
 
role
 
of
 
automatic
 
and
 
nonautomatic
 
processes.
 
Psychol.
 
Rev.
 
97,
 
147â€“168
 
(1990).
 
45.
 
 
Zubieta,
 
J.-K.
 
et
 
al.
 
Regional
 
cerebral
 
blood
 
flow
 
responses
 
to
 
smoking
 
in
 
tobacco
 
smokers
 
after
 
overnight
 
abstinence.
 
Am.
 
J.
 
Psychiatry
 
162,
 
567â€“577
 
(2005).
 
46.
 
 
Brody,
 
A.
 
L.
 
et
 
al.
 
Brain
 
metabolic
 
changes
 
during
 
cigarette
 
craving.
 
Arch.
 
Gen.
 
Psychiatry
 
59,
 
1162â€“1172
 
(2002).
 
47.
 
 
Shiffman,
 
S.
 
et
 
al.
 
Smoker
 
reactivity
 
to
 
cues:
 
effects
 
on
 
craving
 
and
 
on
 
smoking
 
behavior.
 
J.
 
Abnorm.
 
Psychol.
 
122,
 
264â€“280
 
(2013).
 
48.
 
 
Conklin,
 
C.
 
A.,
 
Perkins,
 
K.
 
A.,
 
Robin,
 
N.,
 
McClernon,
 
F.
 
J.
 
&
 
Salkeld,
 
R.
 
P.
 
Bringing
 
the
 
real
 
world
 
into
 
the
 
laboratory:
 
Personal
 
smoking
 
and
 
nonsmoking
 
environments.
 
Drug
 
Alcohol
 
Depend.
 
111,
 
58â€“63
 
(2010).
 
49.
 
 
Conklin,
 
C.
 
A.
 
Environments
 
as
 
cues
 
to
 
smoke:
 
Implications
 
for
 
human
 
extinction-based
 
research
 
and
 
treatment.
 
Exp.
 
Clin.
 
Psychopharmacol.
 
14,
 
12â€“19
 
(2006).
 
50.
 
 
Wang,
 
A.-L.
 
et
 
al.
 
Content
 
Matters:
 
Neuroimaging
 
Investigation
 
of
 
Brain
 
and
 
Behavioral
 
Impact
 
of
 
Televised
 
Anti-Tobacco
 
Public
 
Service
 
Announcements.
 
Journal
 
of
 
Neuroscience
 
33,
 
7420â€“7427
 
(2013).
 
51.
 
 
Falk,
 
E.
 
B.,
 
Berkman,
 
E.
 
T.
 
&
 
Lieberman.
 
From
 
neural
 
responses
 
to
 
population
 
behavior:
 
neural
 
focus
 
group
 
predicts
 
population-level
 
media
 
effects.
 
Psychol.
 
Sci.
 
23,
 
439â€“445
 
(2012).
 
52.
 
 
Falk,
 
E.
 
B.
 
et
 
al.
 
Functional
 
brain
 
imaging
 
predicts
 
public
 
health
 
campaign
 
success.
 
Soc.
 
Cogn.
 
Affect.
 
Neurosci.
 
11,
 
204â€“214
 
(2016).
 
53.
 
 
Pegors,
 
T.
 
K.,
 
Tompson,
 
S.,
 
Oâ€™Donnell,
 
M.
 
B.
 
&
 
Falk,
 
E.
 
B.
 
Predicting
 
behavior
 
change
 
from
 
persuasive
 
messages
 
using
 
neural
 
representational
 
similarity
 
and
 
social
 
network
 
analyses.
 
Neuroimage
 
157,
 
118â€“128
 
(2017).
 
54.
 
 
Cooper,
 
N.,
 
Bassett,
 
D.
 
S.
 
&
 
Falk,
 
E.
 
B.
 
Coherent
 
activity
 
between
 
brain
 
regions
 
that
 
code
 
for
 
value
 
is
 
linked
 
to
 
the
 
malleability
 
of
 
human
 
behavior.
 
Sci.
 
Rep.
 
7,
 
[ZIP_CODE]
 
(2017).
 
55.
 
 
Green,
 
A.
 
E.
 
et
 
al.
 
Young
 
Adult
 
Smokersâ€™
 
Neural
 
Response
 
to
 
Graphic
 
Cigarette
 
Warning
 
Labels.
 
Addict
 
Behav
 
Rep
 
3,
 
28â€“32
 
(2016).
 
56.
 
 
Cooper,
 
N.,
 
Tompson,
 
S,
 
Oâ€™Donnell,
 
MB
 
&
 
Falk,
 
EB.
 
Brain
 
activity
 
in
 
self-
 
and
 
value-related
 
regions
 
in
 
response
 
to
 
online
 
antismoking
 
messages
 
predicts
 
behavior
 
change.
 
Journal
 
of
 
Media
 
Psychology
 
27,
 
93â€“108
 
(2015).
 
57.
 
 
Tompson,
 
S.,
 
Lieberman,
 
M.
 
D.
 
&
 
Falk,
 
E.
 
B.
 
Grounding
 
the
 
neuroscience
 
of
 
behavior
 
change
 
in
 
the
 
sociocultural
 
context.
 
Current
 
Opi[INVESTIGATOR_510068]
 
5,
 
58â€“63
 
(2015).
 
58.
 
 
Vezich,
 
S.,
 
Falk,
 
E.
 
B.
 
&
 
Lieberman,
 
M.
 
D.
 
Persuasion
 
neuroscience:
 
new
 
potential
 
to
 
test
 
dual
 
process
 
theories.
 
Social
 
Neuroscience:
 
Biological
 
approaches
 
to
 
social
 
Psychology.
 
New
 
York:
 
Psychological
 
Press.
 
Google
 
Scholar
 
(2015).
 
59.
 
 
Falk,
 
E.
 
B.,
 
Berkman,
 
E.
 
T.,
 
Whalen,
 
D.
 
&
 
Lieberman.
 
Neural
 
activity
 
during
 
health
 
messaging
 
predicts
 
reductions
 
in
 
smoking
 
above
 
and
 
beyond
 
self-report.
 
Health
 
Psychol.
 
30,
 
V2025-06
 

 
177â€“185
 
(2011).
 
60.
 
 
Falk,
 
E.
 
B.,
 
Berkman,
 
E.
 
T.,
 
Mann,
 
T.,
 
Harrison,
 
B.
 
&
 
Lieberman,
 
M.
 
D.
 
Predicting
 
persuasion-induced
 
behavior
 
change
 
from
 
the
 
brain.
 
J.
 
Neurosci.
 
30,
 
8421â€“8424
 
(2010).
 
61.
 
 
Falk,
 
E.
 
B.,
 
Cascio,
 
C.
 
N.
 
&
 
Coronel,
 
J.
 
C.
 
Neural
 
Prediction
 
of
 
Communication-Relevant
 
Outcomes.
 
Commun.
 
Methods
 
Meas.
 
9,
 
30â€“54
 
(2015).
 
62.
 
 
Falk,
 
E.
 
B.
 
et
 
al.
 
Self-affirmation
 
alters
 
the
 
brainâ€™s
 
response
 
to
 
health
 
messages
 
and
 
subsequent
 
behavior
 
change.
 
Proceedings
 
of
 
the
 
National
 
Academy
 
of
 
Sciences
 
112,
 
1977â€“1982
 
(2015).
 
63.
 
 
Cascio,
 
C.
 
N.
 
et
 
al.
 
Buffering
 
social
 
influence:
 
neural
 
correlates
 
of
 
response
 
inhibition
 
predict
 
driving
 
safety
 
in
 
the
 
presence
 
of
 
a
 
peer.
 
J.
 
Cogn.
 
Neurosci.
 
(2014).
 
64.
 
 
Cascio,
 
C.
 
N.,
 
Dal
 
Cin,
 
S.
 
&
 
Falk,
 
E.
 
B.
 
Health
 
communications:
 
Predicting
 
behavior
 
change
 
from
 
the
 
brain.
 
in
 
Social
 
Neuroscience
 
and
 
Public
 
Health
 
(ed.
 
Hall,
 
P.
 
A.)
 
57â€“71
 
(Springer
 
New
 
York,
 
2013).
 
65.
 
 
Berkman,
 
E.
 
T.
 
&
 
Falk,
 
E.
 
B.
 
Beyond
 
Brain
 
Mappi[INVESTIGATOR_007]:
 
Using
 
Neural
 
Measures
 
to
 
Predict
 
Real-World
 
Outcomes.
 
Curr.
 
Dir.
 
Psychol.
 
Sci.
 
22,
 
45â€“50
 
(2013).
 
66.
 
 
Berkman,
 
E.
 
T.,
 
Falk,
 
E.
 
B.
 
&
 
Lieberman,
 
M.
 
D.
 
In
 
the
 
trenches
 
of
 
real-world
 
self-control:
 
neural
 
correlates
 
of
 
breaking
 
the
 
link
 
between
 
craving
 
and
 
smoking.
 
Psychol.
 
Sci.
 
22,
 
498â€“506
 
(2011).
 
67.
 
 
Kang,
 
Y.,
 
Oâ€™Donnell,
 
M.
 
B.,
 
Strecher,
 
V.
 
J.
 
&
 
Falk,
 
E.
 
B.
 
Dispositional
 
Mindfulness
 
Predicts
 
Adaptive
 
Affective
 
Responses
 
to
 
Health
 
Messages
 
and
 
Increased
 
Exercise
 
Motivation.
 
Mindfulness
 
 
8,
 
387â€“397
 
(2017).
 
68.
 
 
Falk,
 
E.
 
B.,
 
Morelli,
 
S.
 
A.,
 
Welborn,
 
B.
 
L.,
 
Dambacher,
 
K.
 
&
 
Lieberman,
 
M.
 
D.
 
Creating
 
buzz:
 
the
 
neural
 
correlates
 
of
 
effective
 
message
 
propagation.
 
Psychol.
 
Sci.
 
24,
 
1234â€“1242
 
(2013).
 
69.
 
 
Oâ€™Donnell,
 
M.
 
B.,
 
Falk,
 
E.
 
B.
 
&
 
Konrath,
 
S.
 
Big
 
data
 
in
 
the
 
new
 
media
 
environment.
 
Behav.
 
Brain
 
Sci.
 
37,
 
94â€“95
 
(2014).
 
70.
 
 
Lopez,
 
R.
 
B.
 
et
 
al.
 
A
 
balance
 
of
 
activity
 
in
 
brain
 
control
 
and
 
reward
 
systems
 
predicts
 
self-regulatory
 
outcomes.
 
Soc.
 
Cogn.
 
Affect.
 
Neurosci.
 
12,
 
832â€“838
 
(2017).
 
71.
 
 
Falk,
 
E.
 
B.
 
et
 
al.
 
Neural
 
Responses
 
to
 
Exclusion
 
Predict
 
Susceptibility
 
to
 
Social
 
Influence.
 
J.
 
Adolesc.
 
Health
 
Care
 
54,
 
S22â€“S31
 
(2014).
 
72.
 
 
Brewer,
 
J.
 
A.,
 
Worhunsky,
 
P.
 
D.,
 
Carroll,
 
K.
 
M.,
 
Rounsaville,
 
B.
 
J.
 
&
 
Potenza,
 
M.
 
N.
 
Pretreatment
 
brain
 
activation
 
during
 
stroop
 
task
 
is
 
associated
 
with
 
outcomes
 
in
 
cocaine-dependent
 
patients.
 
Biol.
 
Psychiatry
 
64,
 
998â€“1004
 
(2008).
 
73.
 
 
Kosten,
 
T.
 
R.
 
et
 
al.
 
Cue-induced
 
brain
 
activity
 
changes
 
and
 
relapse
 
in
 
cocaine-dependent
 
patients.
 
Neuropsychopharmacology
 
31,
 
644â€“650
 
(2006).
 
74.
 
 
Paulus,
 
M.
 
P.,
 
Tapert,
 
S.
 
F.
 
&
 
Schuckit,
 
M.
 
A.
 
Neural
 
activation
 
patterns
 
of
 
methamphetamine-dependent
 
subjects
 
during
 
decision
 
making
 
predict
 
relapse.
 
Arch.
 
Gen.
 
Psychiatry
 
62,
 
761â€“768
 
(2005).
 
75.
 
 
Chua,
 
H.
 
F.
 
et
 
al.
 
Self-related
 
neural
 
response
 
to
 
tailored
 
smoking-cessation
 
messages
 
predicts
 
quitting.
 
Nat.
 
Neurosci.
 
14,
 
426â€“427
 
(2011).
 
76.
 
 
Baek,
 
E.
 
C.,
 
Scholz,
 
C.,
 
Oâ€™Donnell,
 
M.
 
B.
 
&
 
Falk,
 
E.
 
B.
 
The
 
Value
 
of
 
Sharing
 
Information:
 
A
 
Neural
 
Account
 
of
 
Information
 
Transmission.
 
Psychological
 
Science
 
28,
 
851â€“861
 
(2017).
 
77.
 
 
Scholz,
 
C.
 
et
 
al.
 
A
 
neural
 
model
 
of
 
valuation
 
and
 
information
 
virality.
 
Proc.
 
Natl.
 
Acad.
 
Sci.
 
U.
 
S.
 
A.
 
114,
 
2881â€“2886
 
(2017).
 
 
 
V2025-06
 
